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     Radiation-induced lung injury is a common adverse effect in patients receiving thoracic 
irradiation and for which, there is currently no effective therapy. Using a murine model of 
thoracic irradiation, we found that mice deficient in either the chemokine CCL3 or one of its 
receptors, CCR1, are significantly protected from radiation lung injury. This protected 
phenotype includes improved survival, virtually no pneumonitis or fibrosis, and preserved 
lung function when compared to wild-type mice. We further showed that a specific CCR1 
inhibitor, BX471 provided similar protection. Therefore, CCR1 is a promising target for 
reducing radiation lung injury.  
     To investigate the mechanisms by which CCL3/CCR1 signalling mediates radiation lung 
injury, we evaluated their influence on lung inflammation after irradiation. When compared 
with irradiated WT mice, irradiated CCL3- and CCR1-deficient mice had less lung 
infiltration of CD4
+ 
and CD8
+ 
T cells; however, CD4-deficient mice showed only partial 
protection, while CD8-deficient mice had slightly worse fibrosis. We further analyzed 
inflammatory cytokines and different subsets of CD4
+ 
lymphocytes, T
H
1, T
H
2, T
H
17 and 
Treg cells, in our model. We found no differences in lung Foxp3
+ 
Treg cells between WT and 
CCR1-deficient mice. Notably however, irradiated CCR1-deficient mice had less mRNA 
 ii
expression of the T
H
2 cytokines, IL-4 and IL-13, suggesting that T
H
2 cells may mediate 
radiation lung injury. In addition, the T
H
2-enhanced IL-10/12 double knockout mice (IL-
10/12
-/-
) have increased expression of IL-13 and IL-4 with an associated earlier onset and 
enhanced degree of lung fibrosis. Even more striking was our finding that irradiated IL-
10/12
-/- 
mice had an earlier onset of increased IL-17 mRNA expression, as well as increased 
lung infiltration of T
H
17 cells, suggesting that IL-17 cells may also be important mediators in 
radiation lung injury.  
     In summary, our studies show that CCL3 and its receptor, CCR1, are key mediators of 
radiation lung injury that act at least in part by recruiting T
H
17 and T
H
2 cells into the 
irradiated lungs. Furthermore, our findings suggest that the specific inhibitor of CCR1, 
BX471, looks promising as a potential therapeutic agent for ameliorating radiation lung 
injury.  
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I. Introduction 
Radiation-induced lung injury is an adverse effect in 20-40% of patients receiving 
thoracic irradiation [1-6] and is characterized as radiation pneumonitis that in some cases 
progresses to lethal fibrosis [7, 8]. Concurrent chemotherapeutic drug administration 
increases the incidence of radiation pneumopathy to 40-60% [4]. The current treatment, 
steroid therapy, has not only limited efficacy in preventing fibrosis but also has extensive 
side effects [9, 10]. Therefore, understanding the mechanisms of radiation pneumopathy may 
provide insight towards developing novel preventative and therapeutic interventions. 
I.A. General Principles of Radiation Injury 
Radiation causes mitotic cell death [11]. The radiosensitivity of a tissue is directly 
related to its mitotic activity and inversely proportional to the degree of cell differentiation. 
Liver, kidney, bone, muscle, lung and connective tissues are relatively radioresistant, while 
more proliferative tissues (bone marrow, the germinal cells of the testis, and epithelial cells 
of the skin and gut) are relatively radiosensitive. 
Mammalian tissue reactions to radiation consist of cell death and damage followed by 
tissue repair and remodeling. The extent of damage depends on the radiation dose, quality, 
fractionation, and tissue radiosensitivity of the tissues, and the intrinsic repair and 
repopulation capacity; the latter being the most important factor [12]. Both dividing 
progenitor cells and nondividing mature cells are involved in the repair process. The former 
begin to die at their first or second post-irradiation division, while the latter remain relatively 
unaffected by radiation, continue to function and then die at their normal rate. However, the 
damage to the stem cell compartment may prevent efficient repopulation injury is not 
apparent until the number of the functional cells falls below a critical level. Thus, the onset of 
recognizable injury depends on tissue population kinetics, while radiation dose determines 
the severity and duration of the cellular depletion. Therefore, cell death and depletion in 
rapidly dividing tissues, e.g. skin and gut, occurs earlier than in the slowly dividing tissues, 
e.g. kidney and lung. 
Although biochemical, subcellular, and cellular damage takes place immediately after 
ionizing radiation exposure, the clinical and morphological features are often delayed for 
weeks, months, or even years after treatment. For example, only mild changes are seen 6 
weeks after a high dose of irradiation to the lung, but by 6 months there may be widespread 
fibrosis. Acute effects occur within a few weeks after treatment. Later effects appear months 
to years after radiation exposure and may be due to persistent acute damage or a combination 
of changes in the connective tissues, the parenchyma, and the vascular elements. As such, 
radiation injury is commonly classified as acute (early) and late (consequential) effects, 
according to the time of symptom appearance [12].  
 
I.B. Radiation-induced Lung Injury 
1. Pathophysiology 
The lung contains over 40 types of cells, most of which are considered relatively 
radioresistant. However, since the lung has little regenerative capacity, it can not tolerate 
large doses of radiation without risking radiation-induced injury that leads to impaired 
ventilation and diffusion capacity. This radiosensitivity is the major dose limiting factor in 
chest radiotherapy. 
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Radiation-induced lung injury has classically been divided into two distinct, yet still 
tightly connected, phases [6, 7]. The early acute inflammatory phase (radiation pneumonitis) 
typically occurs 1 to 3 months after irradiation and is characterized by alveolar cell depletion, 
with edema and inflammatory cell accumulation in both the interstitial and air spaces. Early 
radiation-induced damage from vascular injury throughout the lungs results in vascular 
congestion and increased capillary permeability. Clinically, patients present with symptoms 
of shortness of breath, congestion, cough, fever, and chest pain. This pneumonitis phase 
usually responds well to steroids. The late radiation fibrosis phase typically occurs about 6 
months after irradiation and is characterized by fibroblast proliferation, collagen 
accumulation, thickening of alveolar septa and destruction of the normal lung architecture 
[13]. Patients may have progressive chronic dyspnea, cough, and chest discomfort with 
radiologic evidence of lung fibrosis, including lung contraction, pleural thickening, tenting of 
the diaphragm, and deviation of trachea or mediastinum toward the irradiation region. Each 
phase of radiation pneumopathy is characterized by distinct histologic lesions [14]. Although 
there is an overlap in the regression of one phase and the progression of the next phase, an 
intermediate exudative phase may occur at few weeks to several months after irradiation, 
which is characterized with marked intra-alveolar edema. Although the histopathologic 
features of radiation-induced lung damage have been well documented, the pathophysiology 
of radiation pneumonitis and fibrosis remains unclear and somewhat controversial. 
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Table 1.1 Histologic changes in radiation-induced lung injury 
 
Phase Events and Histological Lesions Span (week) 
Acute macrophage infiltration of air spaces 
Mononulcear inflammatory cells in alveolar walls 
Edema in the alveolar wall and/or air space 
Fibrin in air space 
 
0-22 
Onset 4 week 
Intermediate Increased septal cellularity (plasma cells, septal cells, 
fibroblasts) 
Large cells (macrophages)  with foamy cytoplasm in 
air space  
 
28-36 
Late (fibrotic) Pathological organization (a replacement of normal 
lung tissue with fibrous connective tissue in the air 
space) 
Collagen deposition 
Beyond 36 
Onset 22 
week 
 
Modified from: Travis EL. The sequence of histological changes in mouse lungs after single 
doses of x-rays. Int J Radiat Oncol Biol Phys. 1980;6(3):345-7. and Van den Brenk, H.A.S 
1971. Radiation effects on the pulmonary system. In Pathology of Padiation, edited by C.C. 
Berjis. Williams and Wilkins, Baltimore, pp. 569-591.  
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The initial oxidative injuries after radiation induce resident fibroblasts, epithelial and 
endothelial cells to alter their expression of inflammatory and chemotactic cytokines. The 
resultant cytokines subsequently serve as mediators to recruit and alter the numbers (or 
populations) of inflammatory cells in the inflamed tissue. Once recruited into the disturbed 
microenvironment, the inflammatory cells are stimulated, producing other mediators and 
initiating a complex ‘‘cytokine cascade.’’ This persistent perturbation of normal cellular 
communication can expand the inflammatory cell population, leading to an overt, 
functionally significant, pneumonitis. In addition, the activated cells, both inflammatory and 
parenchymal, produce mediators that directly affect the overall pattern of proliferation and/or 
extracellular matrix gene expression of lung fibroblasts, leading to progressively increased 
collagen synthesis and eventually the development of fibrosis. Thus, there are numerous 
cellular and molecular mediators involved in the development of radiation-induced lung 
fibrosis, which makes identifying targets for therapeutic intervention difficult [13, 15, 16]. 
2. Chronic Inflammation and Fibrosis 
A common host defense to lung injury is to trigger an inflammatory response. 
Appropriate repair after tissue injury and inflammation requires resolution of the 
inflammatory response and removal of extracellular matrix breakdown products. Failure to 
resolve inflammation and return to its normal histology and physiologic function can lead to 
a chronic, persistent inflammatory response that often leads to tissue fibrosis. However, the 
relationship between pneumonitis and fibrosis is controversial, not only in radiation models, 
but also in idiopathic lung fibrosis (IPF) and chemical-induced fibrosis [17, 18]. Clinically, 
fibrosis invariably occurs after pneumonitis; however, fibrosis can occur independently and 
even in the absence of an overt pneumonitic phase [7]. For example, there is little 
 5
inflammation in advanced usual interstitial pneumonia (UIP) and idiopathic pulmonary 
fibrosis (IPF) [19]. Also, bleomycin-induced inflammation can occur without fibrosis in mice 
deficient in either the epithelial cell integrin αvß6 (ß6-/-), which activates latent TGF-ß, or 
CD44, a transmembrane adhesion receptor that is involved in T-cell recruitment [20]. 
Furthermore, the endothelial cell adhesion molecule ICAM1-/- mice do not develop 
pneumonitis after irradiation and develop fibrosis only at high doses, which suggests that the 
inflammatory response is not the sole factor underlying the development of radiation-induced 
fibrosis [21]. Lastly, although steroid therapy suppresses radiation pneumonitis, it does not 
alter the ultimate fibrosis in rat, and often in humans [10].  
Evidence supports cellular interactions between lung parenchymal cells and 
inflammatory cells in mediating fibrosis through a variety of cytokines, i.e., proinflammatory 
cytokines, chemokines, adhesion molecules, profibrotic cytokines and growth factors [17, 22]. 
3. Effects on Lung Function 
Many patients (50–90%) receiving irradiation to the lung experience a reduction in 
whole-lung function, as assessed by radiographic and lung function tests [23]. Severe 
respiratory distress occurs when over 75% of the lung is involved with radiation pneumonitis 
wherein alveolar edema obstructs the acini. Radiotherapy-induced lung symptoms can be 
measured by pulmonary function test (PFT) because they are an assessment of whole lung 
function. Clinically, gross physiologic changes do not occur in the lung until 4 to 12 weeks 
after irradiation, usually coincident with the period of clinical pneumonitis. This period is 
associated with a decrease in lung volume. Most patients have a fall in compliance coincident 
with the clinical pneumonitis [1]. Gas exchange abnormalities, e.g. a decrease in diffusion 
capacity and arterial hypoxemia, occur at about the same time, but show some tendency 
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toward recovery after 6 to 12 months. Lung histologic changes correlate with lung function 
abnormalities in several models of lung injury and fibrosis. Lung compliance is decreased 
and tissue elastance is increased in mice 21 days after bleomycin intratracheal instillation 
[24]. Franko used CO uptake to measure respiratory function in mice after irradiation and 
found that a decrease of CO uptake began in all mice between 9 and  12 weeks after a dose of 
9.8 Gy irradiation [18]. Pauluhn et al. used an non-invasive Buxco system to analyze 
radiation-induced pneumonitis and the long-term sequelae [25]. They found reduced 
quasistatic compliance and total lung capacity in mice at 4 months after hemithorax radiation. 
Single-breath carbon monoxide diffusion capacity was also significantly decreased in that 
study. 
4. Management of Radiation Lung Injury 
WR-2721 (amifostine) is a phosphorylated aminothiol and free radical scavenger. It has 
been shown to confer cytoprotection of normal tissues when administrated with radiation 
therapy. This cytoprotection is believed to result from elimination of free radicals produced 
by radiation. Amifostine was shown to significantly reduce acute pneumonitis in patients 
receiving radiation therapy (31% vs 7.4%, p=0.03); however, overall survival was not 
impacted [26]. Amifostine appears not to affect tumor control in cancer patient with radiation 
therapy.  
Angiotensin-converting enzyme inhibitors have also been shown to ameliorate radiation-
induced pneumonitis and lung fibrosis in a rat model [27]. Although superoxide dismutase 
(SOD) analogues have been shown to protect against lung fibrosis in several animal models 
(including radiation), clinical studies on the effects of these drug in patients has not been 
reported yet [28, 29]. Thus, currently corticosteroids are the commonly used agents for 
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treating acute radiation pneumonitis because of their capacity to induce lymphocyte 
apoptosis and reduce the production of pro-inflammatory cytokines. Unfortunately, 
corticosteroid treatment has failed to substantially improve the prognosis for many patients at 
risk for radiation-induced fibrosis. Steroids are also associated with toxicity and an increased 
susceptibility to infections [9, 10]. In summary, there is no proven radioprotective therapy for 
radiation lung injury, especially for the later fibrosis. 
5. Molecular mediators of  radiation pneumopathy 
Radiation-induced pneumonitis and fibrosis is a complex process involving 
proinflammatory and profibrotic cytokines produced by damaged and activated cells that are 
resident or recruited into the lung. Ionizing radiation activates a stress response in 
mesenchymal cells, leading to upregulation of specific transcription factors such as NF-kB, 
c-abl, c-jun, Egr-1 and c-fos [30]. This cellular activation initiates a repair process involving 
many growth factors, cytokines, and chemokines. A key role for proinflammatory cytokines 
is also suggested by detecting, blocking, or augmenting cytokine expression in various 
experimental models of lung fibrosis [31, 32].  Increased inflammatory cytokine mRNA and 
proteins have been observed in the progression of radiation-induced lung injury [16]. There 
are also distinct temporal and spatial changes in proinflammatory cytokine gene expression 
in bronchoalveolar lavage (BAL) and whole lungs of the irradiated mice [33]. 
Transforming growth factor (TGF-β) is the pivotal mediator in the fibrotic process. 
TGF-β induces the phenotypic modulation of human lung fibroblasts to myofibroblasts, the 
chemotactic recruitment of fibroblasts, the synthesis of  collagen and various other 
extracellular matrix components (fibronectin, glycosaminoglycans, and proteoglycans), and 
reduces the degeneration of extracellular matrix by inhibiting the generation of serine 
 8
proteases, metalloproteinases, and collagenases [34, 35].  In addition, TGF-ß is a potent 
stimulator of angiogenesis and a chemoattractant for monocytes and macrophages, inducing 
its own production in an autocrine fashion. Several cellular sources of TGF-ß appear to be 
activated during lung fibrosis. The importance of these sources may vary at different stages of 
the reparative process and in different forms of lung disease. After irradiation in mice, TGF-ß 
expression increases from macrophages during the early phase of lung injury, whereas later 
on, type II pneumocytes and fibroblasts may serve as important sources of TGF-ß [36]. 
Patients with higher plasma TGF-ß, IL-1, or IL-6, before or during irradiation, have a higher 
risk of developing pneumonitis [37, 38]. TGF-β in BAL fluid was upregulated and peaked 
between 3 and 6 weeks after irradiation, coincident with the initial influx of inflammatory 
cells and preceding the pulmonary fibrosis, suggesting a pathogenetic role of TGF-β in the 
development of radiation fibrosis in humans [39].  Work by Franko et al. showed 10% of 
fibroblasts were active-TGF-β positive by immunohistochemical stain in the lesions in the 
early stage of fibrosis while only 0.7% of cells were positive in lesions without fibrosis. They 
concluded that the association of active TGF-β with fibroblasts was related to the initiation of 
fibrosis in this model [40]. 
TGF-β also downregulates the inflammatory response, while promoting fibrosis [20]. 
TGF-β released soon after tissue injury serves primarily as a proinflammatory molecule 
because of its potent neutrophil chemotactic effects, but then, its function switches to 
promote the resolution of inflammation and repair during the healing phase. TGF-β might 
suppress, rather than induce, tissue remodeling in some settings. TGF-β-producing regulatory 
T cells increased IL-10 production and then suppressed bleomycin-induced lung fibrosis 
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[41]. Therefore, it seems that macrophage-derived TGF-β is often pro-fibrotic, whereas Treg-
cell-derived TGF-β may be suppressive.  
Several members of the fibroblast growth factor (FGF) family stimulate DNA 
synthesis in endothelial and epithelial cells and also protect endothelial cells from radiation-
induced damage by inhibiting apoptosis [42]. bFGF is produced by endothelial cells within 
hours after radiation and promotes fibroblast growth and differentiation. Serum 
concentrations of bFGF (together with TNF-α and IL-6) are consistently greater in patients 
undergoing lung radiotherapy [38, 43].  
TNF-α is produced by activated macrophages during the fibrotic process and has 
proinflammatory and immunoregulatory effects. Various cytokines control the production of 
TNF- : IL-2, IFN, and GM-CSF stimulate its production, whereas IL-6 and TNF-  inhibit it. 
TNF-α stimulates fibroblast proliferation and the secretion of extracellular matrix proteins, 
collagenase production, and other proinflammatory cytokines, e.g., IL-1 and IL-6. Treatment 
with a recombinant TNF-α receptor that blocks TNF-α activity, ameliorates the fibrotic 
lesions in lungs of bleomycin-treated mice [44]. TNF-α is implicated in the early phase of 
radiation pneumonitis as irradiated C3HeB/Fe mice show increased macrophage-produced 
TNF-α in BAL; however, this reaction settles within 4 months [45]. Nonetheless, there are 
only minor differences in TNF-α expression  in the fibrosis-sensitive strain, C57LB6/J, and 
nonsensitive strain, C3HeB/Fe, suggesting that it may not be biologically meaningful in 
radiation pneumopathy [40]. 
A number of cytokines involved in T cell subset differentiation have also been 
implicated in radiation pneumopathy. Naive murine CD4+ T helper cells (TH0) can be 
induced to differentiate towards type 1 T helper (TH1), TH2, and TH17 phenotypes according  
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Table 1.2 Cytokines implicated in lung fibrosis 
Cytokine Species Model Change Reference 
TGF-β Human XRT Increased TGF-ß expression  [37] 
TGF-β mouse XRT Increased TGF-ß expression [27] 
TGF-β Rat XRT Increased TGF-ß in IHC [46] 
bFGF Human XRT Increased bFGF expression  [38, 43] 
TNF-α human XRT Increased TNF-α in BAL [45] 
IL-1β human XRT Increased TNF-α in BAL [38] 
IL-6 human XRT Increased IL-6 in BAL [43] 
IL-4 Rat XRT Increased IL4 in tissue and BAL  
IL-4 human IPF Increased IL4 in tissue and BAL [47] 
IL-10 mouse XRT Increased IL-10 expression [48] 
bFGF- basic fibroblast growth factor; TNF-α-tumor necrosis factor-alpha 
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to the local cytokine milieu (Figure 1.1). There is also another CD4+ T subset, regulatory T 
cells (Treg). The presence of interleukin IL-12 [signaling through STAT-4] skews 
differentiation towards TH1, IL-4 (signaling through STAT-6) towards TH2, TGF-β towards 
Treg, and IL-6 and TGF-β towards TH17 [49, 50]. TH1 cells produce mainly the pro-
inflammatory cytokines IL-1, IL-2, IL-12, IL-15, IL-18, IFN-γ and lymphotoxin (TNF-β), 
while TH2 cells produce IL-4, IL-5, IL-6, and IL-13. Both TH1 and TH2 produce IL-3 and 
granulocyte-macrophage colony-stimulating factor (GM-CSF), both of which stimulate 
leukocyte production from bone marrow. TH1 cells orchestrate responses to pathogens that 
have overcome epithelial barriers and attack internal tissues. Conversely, TH2 cells arm 
epithelial and mucosal sites to make life difficult for pathogens attempting to prosper there. 
The TH1 cytokines IL-2, IFN-γ, and TNF-β activate cytotoxic T cells (Tc) and macrophages 
to stimulate the cellular immunity and inflammation associated with autoimmune disorders 
and allograft rejection, whereas the TH2 cytokines IL-4, IL-5, IL-6, and IL-10 stimulate 
antibody production by B cells and mediate allergic inflammation and chronic 
fibroproliferative disorders, such as asthma, atopic dermatitis, IPF and systemic sclerosis. 
TH17 cells have been shown to express IL-17, IL-17F, IL-21 and IL-22 (and IL-26 in humans) 
and to regulate inflammatory responses [51]. 
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Figure 1.1 General scheme of T-helper-cell differentiation. Naive CD4+ T cells, after 
activation by signaling through the T-cell receptor and co-stimulatory molecules such as 
CD28 and inducible T-cell co-stimulator (ICOS), can differentiate into one of three lineages 
of effector T helper (TH) cells — TH1, TH2 or TH17 cells. These cells produce different 
cytokines and have distinct immunoregulatory functions. Interferon-γ (IFN-γ ) produced by 
TH1 cells is important in the regulation of antigen presentation and cellular immunity. The 
TH2-cell cytokines interleukin-4 (IL-4), IL-5 and IL-13 regulate B-cell responses and anti-
parasite immunity and are crucial mediators of allergic diseases. TH17 cells have been shown 
to express IL-17, IL-17F, IL-21 and IL-22 (and IL-26 in humans) and to regulate 
inflammatory responses. TGF-β, transforming growth factor-β. Cheng Dong, Nat Rev 
Immunol. 2008, 8:337-48. 
 
 
 
 
 
 
 
 
 
 
 
 13
The opposing effects of TH1 and TH2 cytokines have been shown in a number of 
studies [34]. The predominant TH1 cytokine IFN-γ inhibits the proliferation of TH2 cells, 
while IFN-γ and IL-2 stimulate B cells to secrete IgG2a and inhibit secretion of IgG1 and  
IgE. The TH2 cytokine IL-10 inhibits TH1 secretion of IFN-γ and IL-2; it also suppresses 
Class II MHC expression and the production of bacterial killing molecules and inflammatory 
cytokines by macrophages. IL-4 stimulates B cells to secrete IgE and IgG1. The balance 
between TH1 and TH2 activity may steer the immune response in the direction of cell-
mediated or humoral immunity.  
 In fibrosis, IL-4, IL-5 and IL-13, the signature TH2 cytokines, are important 
mediators of fibroblast activation and have powerful anti-inflammatory effects while IFN-γ 
has profound suppressive effects on the production of extracellular matrix proteins [52]. For 
example, a predominant TH2 cytokine (IL-4 and IL-5) profile is seen in IPF by 
immunostaining and in situ hybridization of open lung biopsy specimens, while BAL 
findings in sarcoidosis and hypersensitivity pneumonitis were characterized by a TH1-
dominant profile [47, 53]. A shift from a TH1 to a TH2 cytokine profile is likely to be a key 
event in the progression of inflammation to fibrosis in IPF.  TH1 cytokines, particularly IFN-γ,  
appear to have antifibrotic effects by inhibiting myofibroblasts [54, 55]. 
IL-1 is mainly produced by activated macrophages, but also by other cells, e.g., 
endothelial cells. There are two nearly equivalent functional forms of IL-1, designated IL-1α 
and IL-1β. Both forms of IL-1 bind to the same receptors (type 1 and type 2 receptors) and 
show similar biological activities. They act on target cells both directly and via the induction 
of further cytokines. The main biological activity of IL-1 is the stimulation of TH1 cells, 
which are induced to secrete IL-2 and to express IL-2 receptors. IL-1 also acts directly on B 
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cells, promoting their proliferation and the synthesis of immunoglobulins. IL-1 also 
upregulates adhesion molecule expression on endothelial cells and is a strong 
chemoattractant for leukocytes. Increased production of both IL-1α and IL-1β was observed 
in alveolar macrophages in vitro after radiation [56]. IL-1β has been shown to stimulate IL-6 
production by human lung fibroblasts [43]. IL-1β increased in the lungs of irradiated fibrosis-
resistant (C3H/HeJ) mice, but not in fibrosis-sensitive (C57BL/6), suggesting it may have a 
protective function in radiation lung injury [57].  
IL-6 is an acute phase proinflammatory cytokine produced by activated alveolar 
macrophages, T helper lymphocytes, lung fibroblasts, and Type II pneumocytes. High pre-
treatment or post-treatment levels of IL-6 and IL-1α correlated with the development of 
radiation pneumonitis in humans, suggesting that pre-treatment IL-6 levels may serve as a 
predictor for radiation pneumonitis [38, 43]. 
 IL-10 is a known suppressive cytokine for T-cell proliferation and cytokine 
production. Although IL-10 is produced mainly by TH2 cells,  Treg, TH0, TH1, B cells, 
monocytes and keratinocytes are additional source of IL-10 [58]. IL-10 mRNA expression 
increases in a radiation-dose-dependent manner and may also explain some of the 
immunosuppressive effects of ionizing radiation. IL-10 has shown some efficacy in the 
treatment of fibrosis. Mice treated with IL-10 had less carbon tetrachloride (CCl4)-induced 
liver fibrosis [59] and bleomycin-induced lung fibrosis [59, 60]. IL-10 inhibited radiation-
induced transendothelial cell migration by leukocytes in mice through the inhibition of 
ICAM-1 expression, but the IL-10 deficiency had little effect on the development of fibrosis 
[48].  
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IL-4 has potent pro-fibrotic activity. IL-4 is increased in idiopathic pulmonary 
fibrosis [53], cryptogenic fibrosing alveolitis [47], periportal fibrosis [61], and in the lungs of 
rats undergoing hemi-thoracic radiation [62]. In addition, neutralizing antibody for IL-4 
consistently reduced hepatic collagen deposition in schistosomiasis infected mice [63]. 
IL-5 exacerbates bleomycin-induced lung fibrosis, but IL-5-/- mice had no 
improvement in fibrosis, suggesting that IL-5 may act as an amplifier, rather than as a direct 
mediator, of lung fibrosis [64].  
IL-12 acts a central mediator of the cell-mediated immune response by promoting 
TH1 development. Cells known to produce IL-12 include macrophages, dendritic cells, 
monocytes, Langerhans cells, neutrophils, and keratinocytes. Biologically active mouse IL-
12 is a disulfide-linked, 70 kDa (p70) heterodimeric glycoprotein composed of a 40 kDa (p40) 
subunit and a 35 kDa (p35) subunit. While the p40 and p35 subunits by themselves do not 
have IL-12 activity, the p40 homodimer has been shown to bind the IL-12 receptor and is an 
IL-12 antagonist. The p40 subunit was previously shown to be secreted in excess of the 
heterodimeric IL-12 in cells expressing both the p35 and p40 mRNAs; however, free p35 
subunits were not detected in supernatants of cultured cells expressing either only p35 or 
both p35 and p40 mRNAs.  
IL-13 and IL-4 have many similar functions as both use the same IL-4 receptor -
chain (IL-4R ) and STAT-6 signaling pathway. IL-13 has been shown to play a dominant 
role in the pathogenesis of pulmonary fibrosis in some experimental models [65-67]. 
Subepithelial airway fibrosis was induced without any additional inflammatory stimulus, by 
overexpressing IL-13 in the mouse lung whereas IL-13-specific antibodies markedly reduced 
collagen deposition in the lungs of animals that were challenged with Aspergillus fumigatus 
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conidia or bleomycin. In addition to direct effects on fibroblasts that support 
fibroproliferation, IL-13 stimulates the production of CC-chemokines by epithelial cells. 
In summary, although many studies support TH2 cells as the main mediators in IPF 
and  other models of fibrosis [34, 68], it is still unknown whether radiation-induced lung 
fibrosis may be TH1 or TH2-mediated. 
6. Cellular  Mediators of  Radiation Pneumopathy 
The lung parenchyma consists of respiratory bronchioles, alveolar ducts, and alveoli. 
The alveolar wall is covered by endothelium that is connected to the epithelium by a 
basement membrane. Alveolar epithelial and endothelial cells, as well as fibroblasts, 
synthesize and maintain the basement membrane. The interalveolar interstitial space is 
composed of fibroblasts, alveolar macrophages, and extracellular matrix (ECM). ECM 
contains proteoglycans, fibronectin, laminin, entactin, and Type IV and VII collagen. The 
quantity and quality of the ECM changes during radiation pneumopathy, via gene activation 
in fibroblasts. Increases in  the collagens I/III/IV and fibronectin occurs early and persists 
until 8 weeks after radiation [69].  
There are two types of alveolar epithelial cells: type I and type II pneumocytes.  The 
squamous type I pneumocytes cover ≥90% of the surface of the alveolar epithelium. The 
cuboidal type II pneumocytes (granular pneumocytes) synthesize and secrete the lung 
surfactant that covers the alveolar surface and regulates surface tension. When injury occurs, 
type I pneumocytes are the first to be affected. Type I pneumocyte apoptosis leads to the 
proliferation of type II pneumocytes, thus inducing a regenerative response to repopulate the 
alveolar epithelium. Changes in type II pneumocytes are  consistent findings in both clinical 
and experimental radiation pneumonitis. Because of their role in synthesizing surfactant, a 
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loss or change in the normal physiology of type II pneumocytes can profoundly alter lung 
function. Type II cell hyperplasia is a nonspecific marker of alveolar injury and repair and 
has been reported following other lung insults [70]. These cells respond by increasing 
alveolar surfactant production during the first 2–6 weeks after irradiation [23]. Thus, the 
early response to radiation is thought to be primarily driven by lung epithelial and endothelial 
cells [15]. 
 There are two types of fibroblasts in lung interstitium: the common fibroblast, 
which parallels the epithelium and is intimately connected to the fiber elements of the ECM, 
and the myofibroblast, which is stellate and oriented perpendicularly to the alveolar wall. In 
response to injury, fibroblasts transdifferentiate into myofibroblasts, migrate, and generate 
the matrix components of scar tissue [7]. Myofibroblasts express matrix metalloproteinase 
(MMPs) and tissue inhibitors of metalloproteinase (TIMPs), through which they regulate the 
degradation of matrix components [71]. Myofibroblasts are either recruited from bone 
marrow, i.e. fibrocyte (CD45+, Cd34+, collagen I+), or are derived by epithelial-mesenchymal 
transdifferentiation (EMT) [72-74]. Fibrocytes are associated with skin lesions, lung fibrosis, 
and tumors and contribute to the remodeling response by secreting matrix metalloproteinases 
[75, 76]. Recent data indicate that the CXC and CC chemokine families are involved in 
promoting the mobilization and trafficking of fibrocytes [75-77]. These functions of CXC 
chemokines are important in the pathogenesis of lung fibrosis and other fibroproliferative 
disorders.  
 While lung fibroblasts are probably the most central cell population in the process of 
radiation-induced lung fibrosis, it is clear that regulation of the fibroblast responses to injury 
is influenced by specific interactions with multiple inflammatory cell types. Numerous lung 
 18
inflammatory cells, both resident and recruited, are involved in the development of radiation 
pneumonitis and fibrosis in experimental models. A selective increase of CD4+ T cells was 
observed, peaking 4 weeks after irradiation in the rat lung [62], 70]. A number of 
macrophages and lymphocytes were found in both BAL and lung in mice after irradiation 
[15]. T cell depletion prevents radiation-induced pneumonitis in specific pathogen free (SPF) 
mice, which suggests an autoimmune component to this injury [78]. 
 Activated macrophages produce numerous cytokines with mitogenic or chemotactic 
properties for neutrophils and lymphocytes and also act directly on fibroblasts and 
endothelial cells [7]. Macrophage activation was first described as a TH1 cell–IFN-γ-
mediated process; however, it is now clear that macrophages differentiate into at least two 
functionally distinct populations depending on whether they are exposed to TH1 or TH2 
cytokines. TH1 cytokines activate nitric-oxide synthase 2 (NOS2) expression in classically 
activated macrophages, whereas the TH2 cytokines IL-4 and IL-13 preferentially stimulate 
arginase-1 (ARG1) activity in “alternatively activated” macrophages [79]. Macrophages are 
found at diverse sites of inflammation and have been linked to the process of inflammation 
and repair. Activated macrophages regulate inflammatory cells, tissue debridement, cell 
killing, recruiting and activating myofibroblasts, and regulating spontaneous recovery of 
fibrosis in physiological or aberrant wound healing [80-83]. Macrophages also affect the 
transcription of a variety of other cytokines, chemokines, and growth factors, including 
PDGF, TGFα, TGFβ, FGF2, IL-10, TNF, IL-1a, macrophage-derived chemokine (MDC, 
CCL22), monocyte chemotactic protein 1 (MCP-1; CCL2), CCL3, MIP-1β and regulated 
upon activation, normal T expressed and secreted (RANTES; CCL5). Therefore, it is no 
surprise that alveolar macrophages are another cell population important in the 
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pathophysiology of lung fibrosis. In a hapten-induced lung fibrosis murine model, depletion 
of alveolar macrophages reduced the number of TNF-α-containing cells, as well as the 
number of inflammatory cells recruited into the alveolar space, with subsequent decreased 
collagen deposition [84]. Macrophages were recruited into the lungs of mice and rats after 
thoracic irradiation [15, 46, 85, 86]. The conditioned media of alveolar macrophages isolated 
from irradiated rabbit lungs evoked a substantial proliferation of fibroblasts [86]. Cultured 
alveolar macrophages dramatically increase their TGF-β secretion after radiation. Mice with 
radiation-induced fibrosis exhibit increased TGF-β expression by macrophages during the 
early phase of lung injury that was associated with lung inflammatory foci [36]. The regions 
of inflammatory infiltration and focal fibrotic lesions after irradiation contains numerous 
macrophages [18]. Recruited macrophages have severe hypoxia at 6 months after XRT, 
suggesting that the oxygen consumption by activated macrophages contributes to the 
systemic hypoxia [6]. Although macrophage-derived TGF-ß may promote fibrosis by directly 
activating resident fibroblasts to become collagen-producing myofibroblasts, prior 
macrophage depletion by liposome-clodronate did not influence later cell recruitment [15]. 
Thus, the specific role for alveolar macrophages in radiation-induced lung fibrosis is still 
likely complex and not fully understood. 
Lastly, the role of neutrophils has not been clearly defined; however, at least one 
study suggests that neutrophils are not important in radiation lung injury [38].  
In summary, radiation-induced pneunomitis and fibrosis is a complex multicellular 
process in which the fibroblasts respond to the macrophages, the lymphocytes, the type II 
epithelial cells, and the endothelial cells.  
 
 20
I.C. Chemokines and Chemokine receptors 
1. Chemokine Structure 
Chemokines (chemotactic cytokines) are single polypeptides ranging from 
approximately 70 to 120 KD in length and share 20% to 30% of amino acid sequence identity. 
Chemokines are rich in basic amino acids and contain several four cysteine motifs forming 
disulfide bonds between the first and third cysteines and between the second and fourth 
cysteines [87, 88]. The general structure of chemokines is a β-barrel consisting of 3 anti-
parallel β strands flanked by a basic C-terminal α-helix, a disordered N-terminal region, and 
the connecting loops (Figure 1.2). 
2. Nomenclature 
Chemokines are divided into four subgroups (CXC, CC, C, and CX3C chemokines) 
based on the organization of the first pair of conserved cysteine motifs (Table 2). Chemokine 
receptors are defined by their ability to signal or bind one or more members of the chemokine 
family: CXCR (receptors for CXC chemokines), CCR (receptors for CC chemokines), XCR 
(a receptor for C chemokines), and CX3CR (a receptor for CX3C chemokines) [88, 89].  
3. Chemokine Receptors 
Chemokines are often induced rather than constitutively produced, act locally rather than 
systemically and mediate their effects through 7-transmembrane-spanning G-protein-coupled 
receptors. Most chemokine receptors recognize more than one chemokine and several 
chemokines bind to more than one receptor. Chemokine receptors signal through the G 
protein subunit to directly activate phospholipase C and phosphoinosidide 3-kinase (PI3K) 
and subsequently activate cytoskeletal regulatory kinases, such as FAK, that mediate  
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Figure 1.2 Three-dimensional structure of the CXC chemokine SDF-1 as obtained by 
nuclear magnetic resonance (NMR) analysis in solution. A model ribbon structure is shown 
on the left. On the right, 30 single structures are projected onto each other. This presentation 
shows that the structure of the core is rigid as judged by the fact that it is virtually identical in 
all single views. The amino- and carboxyl-terminal regions, by contrast, can move freely as 
shown by their disordered structure. Crump et al. [90].  
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chemotaxis. A systematic nomenclature for chemokine receptors has been established (Table 
1.3). Chemokine receptor interacts with two main sites on a chemokine, one in the N-
terminal region and the other within an exposed loop of the backbone that extends between 
the second and the third cysteine. The N-terminal binding site is essential for triggering 
signal transduction from the receptor. However, the receptor recognizes the loop region first: 
it is this interaction that is necessary for the correct presentation of the triggering domain. 
Analogues generated by amino-acid deletion or modification of the N-terminal region still 
bind effectively, but do not signal, and thus act as receptor antagonists [91]. 
4. Chemokine Sources and Regulation 
While virtually every cell in the body can produce chemokines, some chemokines are 
produced constitutively by specific cell types. Leukocytes, vascular endothelial cells, smooth 
muscle cells and fibroblasts all have receptors for chemokines (Table 1.4). CXC chemokine 
receptors are primarily expressed by neutrophils and lymphocytes, whereas CC chemokine 
receptors are expressed on a wider range of cells, such as lymphocytes, monocytes, 
macrophages, and basophils. Of interest to our model, T 1 and T 2 cells show distinct 
patterns of chemokine receptor expression: CCR5 and 
H H
CXCR3 are characteristic for T 1 
cells and their expression can be suppressed by IL-10, whereas CCR3 and CCR4 are 
characteristic for T 2 cells and their expression requires the synergistic effects of IL-2 and 
IL-4 
H
H
[92]. Chemokines are also classified by their functions as being either inflammatory or 
homeostatic. Homeostatic chemokines, also called homing lymphoid chemokines, including 
CCL19, CCL21, CXCL12 and CXCL13, are constitutively produced in lymphoid tissue and 
maintain the activity of leukocytes in these organs by directing the traffic and homing of  
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Table 1.3 Chemokines and Chemokine Receptors, Christopherson,2004 [88] 
Name Gene (Human) Protein Synonyms Chemokine Receptor(s) 
C subfamily 
XCL1 SCYC1 Lymphotactin α, SCM-1α, ATAC XCR1 
XCL2 SCYC2 Lymphotactin β, SCM-1β, ATAC XCR2 
CC subfamily 
CCL1 SCYA1 I-309,TCA3 (mouse) CCR8 
CCL2 SCYA2 MCP-1, MCAF, JE (mouse) CCR2 
CCL3 SCYA3 MIP-1α, LD78α CCR1, CCR5 
CCL4 SCYA4 MIP-1β CCR5 
CCL5 SCYA5 RANTES CCR1, CCR3, CCR5 
CCL6 SCYA6 C10 (mouse), MRP-1 (mouse) Unknown 
CCL7 SCYA7 MCP-3 CCR1, CCR2, CCR3 
CCL8 SCYA8 MCP-2 CCR3, CCR5 
CCL9 SCYA9 MRP-2 (mouse), MIP-1γ (mouse) CCR1 
CCL10 SCYA10 CCF18 CCR1 
CCL11 SCYA11 Eotaxin CCR3 
CCL12 SCYA12 MCP-5 (mouse) CCR2 
CCL13 SCYA13 MCP-4, CKβ10 CCR2, CCR3 
CCL14 SCYA14 CC-1,HCC-1,NCC-2,CCCK-1/3,MCIF CCR1, CCR5 
CCL15 SCYA15 HCC-2,Lkn-1,MIP-5,CC-2,NCC-3, MIP-1δ CCR1, CCR3 
CCL16 SCYA16 NCC-4,LEC,HCC-4,LMC,Mtn-1,LCC-1 CCR1, CCR2 
CCL17 SCYA17 TARC CCR4 
CCL18 SCYA18 DC-CK1,PARC,MIP-4,AMAC-1,CKβ7 unknown 
CCL19 SCYA19 Exodus-3,ELC, MIP-3β,CKβ11 CCR7 
CCL20 SCYA20 Exodus-1,MIP-3α,LARC,ST38 (mouse) CCR6 
CCL21 SCYA21 Exodus-2,SLC, 6Ckine,TCA4,CKβ9 CCR7 
CCL22 SCYA22 MDC,ABCD-1,DC/B-CK(mouse) CCR4 
CCL23 SCYA23 MIP-3,MPIF-1,CKβ8-1 CCR1 
CCL24 SCYA24 MPIF-2, CKβ6,Eotaxin-2 CCR3 
CCL25 SCYA25 TECK, CKβ15 CCR9 
CCL26 SCYA26 Eotaxin-3, MIP-4α, CCR3 
CCL27 SCYA27 ALP,Skinkine,ITL,ESkine,CTAK CCR10 
CCL28 SCYA28 MEC CCR3, CCR10 
CXC Subfamily 
CXCL1 SCYB1 GROα,MGSA,N51/KC(mouse),MIP-2 CXCR2,CXCR1 
CXCL2 SCYB2 GROβ, MIP-2α CXCR2 
CXCL3 SCYB3 GROγ, MIP-2β CXCR2 
CXCL4 SCYB4 Platelet factor-4 unknown 
CXCL5 SCYB5 ENA-78 CXCR2 
CXCL6 SCYB6 GCP-2 CXCR1, CXCR2 
CXCL7 SCYB7 PBP,CTAPIII, β-TG, NAP-2 CXCR2 
CXCL8 SCYB8 IL-8 CXCR1, CXCR2 
CXCL9 SCYB9 Mig CXCR3 
CXCL10 SCYB10 γIP-10, crg-2 (mouse) CXCR3 
CXCL11 SCYB11 H174,β-R1, I-TAC,IP-9 CXCR3 
CXCL12 SCYB12 SDF-1α,SDF-1β,PBSF CXCR4 
CXCL13 SCYB13 BLC, BCA-1 CXCR5 
CXCL14 SCYB14 BRAK unknown 
CXCL15 SCYB15 Lungkine,Weche unknown 
CXCL16 SCYB16 Bonzo/STRL33 ligand CXCR6 
CX3CL1 SCYD1 Fractalkine, Neurotactin (mouse) CX3C Subfamily CX3CR1 
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       Table 1.4 Expression of CC Chemokine Receptors in Mouse Leukocyte Populations  
 
 CCR1 CCR2 CCR3 CCR4 CCR5 CCR6 CCR7 CCR8 
T lymphocytes + + + + + + + + 
B lymphocytes  +   + + + + 
Macrophages + +   +   + 
Eosinophils +  +      
Basophils + + +      
Neutrophils +        
Mast cells +  + + +    
Immature Dendritic cells +   + + +   
Mature Dendritic cells     +  +  
NK cells + +  +     
TH1 cells  +   +    
TH2 cells   + +    + 
TH17 cells +* +   +* +   
adapted from Saeki, Curren Pharm Des, 2003, [93] and Von Andrian, N Engl J Med, 1998, 
[94]. Potzl, PLoS ONE, 2008, [95] 
* unpublished data from Dr. Mike Carlson. 
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lymphocytes and dendritic cells [94, 96]. Inflammatory (inducible) chemokines are mainly 
secreted by activated leukocytes, endothelial cells, and epithelial cells and function as 
chemoattractants for neutrophils, monocytes, and other immune cells in the host defenses to 
infection and inflammation. The expression of inflammatory chemokines and their receptors 
is up-regulated by a variety of inflammatory stimuli, e.g., pro-inflammatory cytokines (IL-
1β, TNF- ), or lipopolysaccharides. Inflammatory chemokines include the MCP and MIP 
families, RANTES and eotaxin. These chemokines bind and signal through chemokine 
receptors, CCR1, CCR2, CCR4 and CCR5. T cells express most chemokine receptors 
constitutively; but, under the influence of cytokines, e.g. IL-2, IL-4, IFN-γ, will overexpress 
CCR1, CCR2, CCR5 and CXCR3 and chemotax to RANTES, CCL4, IP-10 and others. 
5. Chemokine Functions 
A vast literature documents the roles of chemokines in a variety of diseases (Table 1.5). 
Their major function is to stimulate leukocyte migration  to sites of tissue injury or 
inflammation, and to activate many cell types, including T lymphocytes and monocytes [87, 
89, 92, 97-99]. Chemokine-induced leukocyte migration is a multistep process as described 
in Figure 1.3. Chemokines also regulate the order and timing of integrin adhesion. For 
example, it has been recently reported that CXCL1 (GROα) and CX3CL1 (fracktalkine) 
mediate the initial firm adhesion whereas CCL2 (MCP-1) is required for subsequent 
leukocyte spreading and diapedesis. Chemokines can stimulate leukocyte degranulation and 
release of inflammatory mediators. CCL2 is a potent stimulator of histamine release from 
basophils [94].  
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 Table 1.5 Chemokine-related diseases 
Category Human diseases Animal models 
 
Autoimmune disease Rheumatoid arthritis; 
systemic lupus  
erythematosis; multiple 
sclerosis 
Autoimmune arthritis (for example, 
collagen-induced arthritis); 
MRL-Faslpr; experimental allergic 
encephalitis 
 
Graft rejection  Heart allograft rejection kidney heterotopic heart allografts; 
sponge allograft rejection allografts 
 
Infection Acute and chronic 
bacterial and viral 
infections (especially HIV 
and mycobacteria) 
Rodent models using the same or 
analogous pathogens; cecal ligation 
and puncture-induced sepsis 
Inflammation or allergy Asthma; arthritis; colitis; 
psoriasis 
Antigen sensitization and anatomically 
specific delivery (for example, inhaled 
antigen challenge in asthma models) 
 
Neoplasia Leukocyte recruitment in 
cancer angiogenesis 
Therapeutic vaccination; 
 in vivo angiogenesis models 
Vascular Atherosclerosis; 
hypertension; 
ischemia-reperfusion 
Hypercholesterolemic rodents; 
genetic models of hypertension 
arterial injury models 
adapted from Baggiolini, Nature, 1998, [91, 96] 
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 Figure 1.3 Chemokines in leukocyte trafficking. The migration of leukocytes from the blood 
into the tissue is a multisetp process involving a series of interaction between leukocytes and 
endothelial cells. Initially, leukocytes in the blood become tethered to endothelial cells and 
roll slowly downstream. Tethering is greatly facilitated by the recognition of L-selectin, E-
selectin, P-selectin glycoprotein ligand 1 [PSGL-1], and α4 integrins by their receptors. E-
selectin and the 4 integrins can tether some leukocytes, but their predominant function is to 
reduce the velocity of rolling. Selectin-mediated bonds arrest leukocytes at the vessel wall, 
resulting in subsequently leukocytes rolling (margination) along the vessel wall under the 
pressure of the blood flow. The rolling leukocytes response to a chemoattractant gradient 
formed by the accumulation of chemokines and other molecules on endothelial cells. These 
rolling leukocytes are then activated through their cell surface chemokine receptors with 
seven transmembrane domains which transmit intracellular signals through G proteins. The 
activating signal induces rapid activation of ß2 integrins, α4 integrins, or both, which then 
bind to members of the endothelial immunoglobulin superfamily, resulting in firm arrest of 
leukocytes. Next, the leukocytes will cross the endothelial cell barrier and follow the 
chemoattractant gradient by a process called extravasation. Finally the leukocytes migrate to 
the site of inflammation. Adapted from Ian Mackay, N Eng J Med, 1998, [94]. 
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Chemokines are clearly important in directing leukocyte trafficking by providing 
chemoattractant gradients as well as by activating integrins. Chemokines that are highly 
expressed in response to the pathogens or other stimuli both initiate and sustain leukocyte 
recruitment to the affected sites. Initially, this process acts to clear the infectious agents or 
irritants with only minimal damage; however, this response can become an overwhelming 
attack on normal tissues, causing autoimmune or other chronic inflammation. Chemokines 
also control the local milieu of inflammatory cytokines. Therefore, locally produced 
chemokines crucially influence disease progression and contribute to the chronicity of many 
types of inflammatory diseases (see Table 1.5). 
The specific leukocytes recruited by chemokines into disease sites reflect the nature 
and chronicity of the diseases. Massive infiltration of neutrophils is the main characteristic of 
many acute inflammatory diseases and correlates with a striking increase in CXC 
chemokines, e.g., IL-8 (CXCL8) and MIP-2 (CXCL2). In contrast, many chronic 
inflammatory diseases often show infiltration of lymphocytes and monocytes/macrophages, 
which is associated with CC chemokines. For example, CCL3 and CCL1 levels are increased 
in rheumatoid arthritis, a chronic inflammatory disease characterized by the infiltration of 
memory T lymphocytes and monocytes [100]. The levels of CCL3 and CCL2 are elevated in 
multiple sclerosis and the deficiency of their receptors, CCR2 or CCR1, diminishs symptoms 
in murine model of EAE [88].  CCL3 and CCR5 are important in graft versus host disease 
(GVHD) because CCL3 attracts CD8+ T lymphocytes to the liver by means of CCR5 
expressed on their surface [101]. In addition to controlling leukocyte trafficking and 
activation, chemokines may help determine the character of local immune responses and 
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contribute to the systemic organization of the immune system by mediating tissue-selective 
trafficking of memory and effector T and B cells [102, 103]. 
In hematopoiesis, chemokines function to guide hematopoietic stem and precursor 
cells to the diverse microanatomical niches in the bone marrow and thymus [89]. CCL3 and 
CCL4 both affect the proliferation of myeloid progenitor cells. CCL3 has complex effects on 
hematopoiesis, enhancing the proliferation of lineage-committed progenitor cells, but 
suppressing the proliferation of  immature progenitor cell proliferation, and mobilizing 
mature and immature myeloid progenitor cells to the blood [93, 104]. 
Some chemokines, such as CXC with ERL motif and CCL2, have very strong 
angiogenic activity and promote capillary formation [97]. These angiogenic properties of 
chemokines may affect tumor growth, inflammation and wound healing, all processes where 
angiogenesis is an important requirement [105].  
Finally, there is overwhelming evidence that chemokines are also involved in tumor 
progression. Many tumor cells and tumor-associated stromal cells generate chemokines, 
which may attract the neutrophils, macrophages and lymphocytes involved in anti-tumor 
immune responses [105, 106]. A variety of effects from these chemokines have been 
described: some promote angiogenesis, metastasis and tumor growth, while others can inhibit 
angiogenesis or improve anti-tumor immunity [105]. The CXCL12-CXCR4 axis facilitates 
tumor metastasis to distant organs and CCL5/RANTES, that binds to CCR1, CCR4, and 
CCR5, has been shown to promote tumor growth [106]. Therefore, small molecule inhibitors 
of these receptors could affect tumor growth, metastases, angiogenesis, and anti-tumor 
responses, depending on the duration and dose given. 
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6. Chemokines and Chemokine Receptors in Airway Diseases 
Many airway diseases, e.g., asthma, chronic bronchitis and chronic obstructive 
pulmonary disease (COPD), are characterized by the influx of inflammatory cells into the 
airway. Given to the important role of chemokines and their receptors in leukocyte migration, 
it is not surprising that they are important in the development of airway diseases (Table 1.6). 
The influx of eosinophils, TH2 cells, and mast cells characterizes asthma [107, 108]. 
Dysregulated CXCL1 expression is associated with reduced Treg activities in allergic asthma 
[109]. In contrast, chronic bronchitis and COPD characteristically have a large influx of 
neutrophils, macrophages and CD8+ lymphocytes. The increased expression of CCL2 and 
CCR2 correlates with the accumulation of mast cells and macrophages in the lungs of COPD 
and chronic bronchitis. Both CCL2 and CCR2 are expressed on mast cells and macrophage, 
suggesting that CCR2 may be an interesting target for therapeutic intervention in the patients 
with COPD and chronic bronchitis [110].  
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Table 1.6  Chemokines in respiratory diseases  
 
CC-chemokine receptors 
 
Chemokine ligands Cell-type/tissue-expression Potential treatment for: 
 
CCR1 MIP-1α, MIP-1β, MCP-
2, MCP-3, RANTES 
NK cells, T lymphocyte, 
macrophage, basophil, 
eosinophil, neutrophil 
 
 
severe asthma 
CCR2 MCP-1,-2,-3,-4,-5 monocytes, memory T 
lymphocytes, B 
lymphocytes, basophils, 
neutrophils  
 
 
COPD, chronic 
bronchitis; asthma 
CCR3 Eotaxin, -2,-3, 
RANTES, MCP-2, -3, -
4, MIP-1α, MIP-1β 
eosinophils, TH2 cells, 
basophils, mast cells 
 
asthma, allergic diseases 
 
CCR4 MDC, TARC, MCP-1 TH2 lymphocytes, NK cells  
 
allergic diseases 
CCR8 I-309, TARC TH2 lymphocytes, 
monocytes in brain, spleen, 
lymph node 
allergic diseases 
 
CXCR1 IL-8, GCP-2, ENA-78 neutrophil, macrophage COPD, chronic 
bronchitis, 
severe asthma 
 
CXCR2 IL-8 IL-8, NAP-2, ENA-78, 
GRO-α,β,γ 
neutrophil, macrophage, 
eosinophil 
COPD, chronic 
bronchitis, severe 
asthma 
Charles Owen, Pulm Pharmaco Ther, 2001,[107] 
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7. Chemokines Receptor Antagonists-New Perspective for Therapy 
With the extensive biological roles for chemokines and their receptors in a variety of 
diseases(Table 1.5 ), the chemokine system may provide novel therapeutic opportunities for 
cardiovascular, allergic, and autoimmune diseases, as well as in transplantation, 
neuroinflammation, cancer and HIV-associated disease [34, 92, 97]. Since chemokines act 
through G-protein coupled seven-transmembrane receptors, and there is a redundancy in 
which chemokines binding to each receptor, neutralization at the chemokine receptor level is 
a more promising target for therapeutic intervention. Thus, identifying which chemokine 
receptors are involved in the pathogenesis of a particular disease is crucial for therapeutic 
drug development. 
Strategies for interfering with chemokine-chemokine receptor system include 
neutralizing antibodies, peptide antagonists and non-peptide antagonists (Table 1.7). Some 
inhibitors specifically bind to certain chemokine receptors, whereas other broad-spectrum 
chemokine inhibitors (BSCIs) inhibit a number of chemokine receptors.  Many chemokine 
inhibitor molecules have been tested by using mutant animals lacking only the desired 
protein expression or by blockade with specific antagonists. Some antagonists have already 
been used successfully in vivo. For example, TAK-779, a CCR5 and CXCR3 antagonist has 
been shown to inhibit the development of experiment-induced arthritis in mice by modulating 
the migration of CCR5+/CXCR3+ T cells into joints [111]. Anti-CCL3 antibodies were 
reported to ameliorate the severity of multiple sclerosis in a murine EAE model [112]. 
Similarly, the CCR1 antagonist, BX-471, effectively reduced symptoms in a rat EAE model 
[93]. BX471 also prolonged survival of cardiac  
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Table 1.7 Chemical and Peptide Antagonists of CC Chemokines and receptors 
 
Inhibitors   Affect Chemokine/Chemokine Receptor    References
 
tRANTES & tMCP-3  antagonists of CCR1, CCR2, CCR3, CCR5        [113]        
(t = truncated) 
 
BX 471   inhibits CCR1 and leukocyte migration        [114]       
 
2q-1    inhibits human & murine CCR1 & CCR3        [115]      
 
4HPs (2,2DPCPV)  inhibits CCL3 / CCR1 binding & signaling      [116, 117]      
 
MCP-3   natural antagonist of CCR5          [118]       
 
AOP-RANTES  inhibits CCR5 & monocyte chemotaxis        [119]       
 
Met-RANTES   inhibits CCR5 & monocyte chemotaxis        [119]            
 
vMIP-II   antagonist at CCR1, 2, 3, 5, and CXCR4        [120]       
 
TAK-779   specifically inhibits CCR5                        [121]       
 
Intrakines   CCR5 specific inhibition          [122]       
 
Hammerhead ribozymes CCR5 specific inhibition          [123]        
 
CCR5∆32   natural inactivating mutant allele         [124]       
 
Met-chemokine β7  specific antagonist of CCR3          [125]        
 
MC148RvMCC-1  blocks CC & CXC chemokine-induced        [126, 127]  
neutrophil, monocyte, and T cell migration   
    
T135kDa protein  broad spectrum chemokine scavenger        [128] 
  
T7    broad spectrum CC chemokine & γ-IFN scavenger  [129]   
    
US28    chemokine sequestration    [130] 
 
Monoclonal ab  blocks CCR5      [131]  
   
IL-10    inhibits chemokine release during endotoxemia        [132] 
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allografts in rats, possibly by inhibiting of monocyte adhesion to inflamed endothelium 
[133].  Thus, chemokine receptor blocking agents may indeed provide important and novel 
therapeutic interventions. 
 
I.D. Chemokines in Radiation-induced Lung Injury 
Chemokines are fundamental regulators of leukocyte homeostasis and inflammation, 
and their antagonism by small molecule chemokine receptor antagonists may be important in 
the future treatment of human respiratory diseases. A number of studies suggest that 
cytokines and chemokines are involved in the pathogenesis of radiation-induced fibrosis and 
other fibrosis models [16, 69, 75, 134-136]. CXCL/CXCR2 is important for neutrophil 
recruitment during the pathogenesis of hyperoxia-induced lung injury [137]. Chemokines are 
also involved in promoting the mobilization and trafficking of circulating mesenchymal 
progenitor cells (also known as fibrocytes) in lung fibrosis [77].  
Although the involvement of chemokines in inflammation is well established, their 
functional role in disease progression, and particularly, in the development of fibrosis, is still 
unclear. The CCL and CCR families have important regulatory roles in fibrotic processes, 
but numerous chemokine signaling pathways are probably involved. Chemokines are 
expressed by a variety of leukocytes implicated in pneumonitis and fibrosis (Table 1.4). 
CCL3 and CCL2 have so far been identified as important pro-fibrotic mediators. CCL3 was 
required for cell recruitment in pneumonitis induced by a variety of pathogens, including 
influenza virus, Aspergillus fumigatus, as well as in GVHD [138, 139]. Lung macrophages 
and epithelial cells are thought to be the main cellular sources of CCL3 [140]. CCL3 specific 
antibodies were shown to significantly reduce bleomycin-induced fibrosis [141, 142]. Studies 
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in murine model of bronchiolitis obliterans syndrome show similar results for CCR2-/- mice 
and for CCL2 antibody-treated WT mice [143]. Thus, both CCL3- and CCL2-mediated 
signaling pathways appear significant in pathogenesis of fibrosis [76, 144].  
I.E. The chemokine receptor CCR1 in Radiation-induced Lung Injury 
The chemokine receptor, CCR1 is expressed by T and B cells, NK cells, dendritic 
cells, macrophages, eosinophils, neutrophils and basophils. CCR1 binds a number of CC 
chemokines, including CCL3, CCL5 (RANTES), CCL2 (MCP-1), CCL7 (MCP-3) and 
CCL15 (MIP-5). These ligands have potent chemotactic activity and can also be produced in 
an autocrine fashion. CCR1 is believed to play a crucial role in the migration of leukocytes to 
the sites of inflammation and in perpetuating inflammatory responses. CCR1 signaling may 
also contribute to tissue damage and inflammation through the enhancement of T cell 
activation, regulation of TH1/TH2 polarization, and the stimulation of macrophage function 
and protease secretion. These properties support CCR1 as an attractive therapeutic target to 
modulate leukocyte infiltration and decrease the associated tissue damage common to the 
autoimmune diseases. 
CCR1 may also be important for murine neutrophil-mediated host defense, since 
CCR1-deficient mice are much more susceptible to Aspergillus fumigatus infection [145]. 
Anti-CCR1 antibodies significantly reduced the accumulation of inflammatory cells and 
collagen deposition, resulting in dramatic improvement in the survival of mice with 
bleomycin-induced lung fibrosis [146]. The CCR1 ligand CCL3 was shown to contribute to 
cellular recruitment during Schistosoma egg granuloma formation [147]. CCR1-/- mice have a 
marked reduction in lung granuloma size after infection with Schistosoma mansoni eggs, this 
effect is associated with increased expression of the TH1 cytokine IFN-γ and decreased 
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expression of the TH2 cytokine IL-4 [145]. Johntson reported a strong correlation between 
elevated CCL3 and development of radiation-induced late effects in fibrosis-sensitive mice 
[16]. The mRNA expression of chemokines BLC, C10, IP-10, CCL2, CCL7, CCL9 and 
CCL5, and the receptors CCR1, CCR2, CCR5 and CCR6 were elevated in fibrosis-sensitive 
(C57BL/6) mice at 26 weeks postirradiation at the dose of 12.5 Gy [148]. Therefore, 
chemokines may cooperate with pro-fibrotic cytokines in the development of fibrosis by 
recruiting inflammatory cells to the sites of tissue damage. Although chemokines and their 
receptors have begun to be investigated in radiation lung injury [16, 99, 136], studies in 
animal models of specific chemokine/receptor inhibitors have not yet been reported. 
Nonetheless, CCR1 is a contributor to airway remodeling in airway diseases and may prove 
to be a therapeutic target.  
We hypothesize that specific chemokines/receptors induced by irradiation may 
mediate the recruitment and activation of inflammatory cells, and thereby may contribute to 
the development of radiation-induced lung injury. And we further hypothesize that inhibitors 
of these chemokines/receptors might represent excellent molecular therapeutic targets for 
reducing or eliminating radiation-induced pneumonitis and subsequent fibrosis.  
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Specific Aims  
(i) To explore the roles of the chemokine, CCL3, and its receptors, CCR1 and 
CCR5, in radiation-induced lung injury. Mouse strains individually 
lacking CCL3, CCR1, and CCR5 are used to compare with radiation-sensitive 
wild type C57BL6/J control mice in radiation-induced lung injury, including 
mortality, pneumonitis, fibrosis, and lung function.  
(ii) To investigate potential therapeutic interventions based on studies in 
protected genotypes, e.g. BX-471 blocking CCR1. 
(iii) To investigate the roles of inflammatory cell subtypes in mediating radiation 
lung injury. We characterize the inflammatory cell infiltrates in the lung after 
radiation by histologic staining and flow cytometry analyses. Mouse strains 
individually lacking certain inflammatory cell subtypes, e.g. CD8 or CD4-
deficient mice, are used in these studies. 
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II. Murine models of radiation lung injury 
II.A. Introduction 
Animals previously used in models of radiation-induced lung injury include rat [22, 
25], mouse [149-151] rabbit [86], and pig [152].  Although mice offer many advantages as a 
model, there are some notable differences in the effects of radiation on the lungs in humans 
compared to mice. For example, the hyaline membrane formation which is an early response 
in human lungs has not been observed in mouse lung [153]. There are substantial strain-
differences in the effects of irradiation on mouse lung. Radiation fibrosis was seen in C57L/J, 
C57BL/6J, and C57BL/10J but not in C3HeB/FeJ, C3/HeJ, or CBA/J [150]. C3H/HeMs mice 
may be able to clear matrix proteins and inflammation more rapidly after irradiation than 
C57BL/6J mice [85]. In contrast, radiation pneumonitis is much more severe in C3/HeJ than 
C57BL/6J mice. Similarly, irradiated C3HeB/FeJ mice develop only classical pneumonitis 
during the early phase, whereas C57L/J mice develop small, tightly packed areas of 
inflammation which undergo fibrosis during the latent period, and exhibit progressive 
fibrosis from large regions of intense inflammation during the early phase [40]. Radiation-
induced lung response susceptibility loci were identified by a genome-wide scan in reciprocal 
backcrossed mice bred from C3H/HeJ and C57BL/6J strains [154]. There was a striking 
difference in the timing and level of expression of cytokines between these two strains after 
lung radiation. For example, TNF-α and IL-1α mRNA levels were increased in irradiated 
C57BL/6 mice but not C3H/HeJ mice, and conversely, IL-1β mRNA levels were increased in 
irradiated C3H/HeJ mice but not C57BL/6 mice [57]. 
Clinically, there is significant individual variation in the incidence and severity of 
lung fibrosis for the radiotherapy patients, suggesting inherent risk factors for developing 
radiation lung fibrosis [155]. Studies by Travis et al. show the spatial heterogeneity of the 
radiosensitivity of murine lungs with critical target cells concentrated in the lung bases [10].  
In general, however, the C57BL/6J is the most commonly used strain for studies of 
radiation-induced lung injury. Moreover, numerous genetically-altered strains are available 
for studying specific individual mediators of radiation lung injury. Thus, we used C57BL/6J 
mice in our model. 
II.B. Materials and Methods 
1. Mice  
All animal studies were performed under approval by the IACUC at the University of 
North Carolina at Chapel Hill. Wild-type mice were purchased from Jackson Laboratories. 
All mice were housed in microisolator cages maintained in a specific pathogen-free 
environment. All of the mice used, except for those used in leukocyte flow cytometry and 
TGF-β1 experiments, were male. Age-matched nonirradiated mice were used in all 
experiments. 
2. Thoracic Irradiation 
Anesthetized mice at the age of 10-12 weeks were immobilized with a lead shield 
excluding all but the thoracic cavity. Animals were then irradiated with a single dose of 14.5 
Gy from a cesium source (J. L. Shepherd & Associates, San Fernando, CA, USA) at a dose 
rate of 1.65 Gy/min. The LD50 for C57BL/6J mice is 14.5 Gy and at this dose survival is 
sufficient to permit adequate numbers of animals for long-term analyses.   
3. Hydroxyproline (HYP) and Pyridinoline (PYR) assays 
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Anesthetized mice were exsanguinated, and the lungs were perfused intracardiacally with 
sterile PBS and removed. Tissue samples were minced, lyophilized for 48 hours until dry, and 
then hydrolyzed in 1 ml of 6 N hydrochloric acid at 120°C for 20 hours. Samples were then 
dried to remove HCl in a speed vacuum for 2 h, resuspended in distilled water, applied to a 
filter Eppendorf tube and spun at 14000 rpm for 5 min. The resultant filtrate was assayed for 
hydroxyproline and pyridinoline by HPLC. 
4. Elastin Assay 
The right lungs of mice were homogenized in 2ml of PBS and then incubated in 0.5ml 
1M acetic acid containing 6mg/ml pepsin for 24h at room temperature with stirring (1500 
rpm).  Supernatants were obtained by centrifugation for 30 minutes at 5,000xg, at 4 oC, and 
then subjected to Fastin elastin assay according to the manufacturer’s protocol (Biocolar CO., 
County Antrim, UK).  
5. Gene Expression Analyses 
Mice were anesthetized and lungs were harvested after perfusion with PBS at 0, 1, 3, 4, 6, 
12, 16, 20, 24, 28 and 32 weeks after thoracic irradiation. RNA was extracted from the left 
lungs using RNeasy Mini kits (QIAGEN INC., Valencia 
CA.). cDNA was generated using SuperScript II reverse transcriptase, dNTPs, and Random 
Hexamer Primer (Invitrogen Corporation, Carlsbad, CA). The resultant cDNA was then 
analyzed by quantitative real-time PCR using the ABI Prism 7000 sequence detection system 
(Applied Biosystems, Foster City, CA). Commercial TaqMan gene expression assays 
(Applied Biosystems, Foster City, CA) were used as the gene-specific probe and primer sets 
for analysis of all genes studied. Data were analyzed using the 2-∆∆CT method as previously 
described [156]. Briefly, data were presented as the fold change in gene expression 
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normalized to an internal control gene (glucuronidase β, Gusb) and relative to a calibrator 
sample (from non-irradiated controls).  
6. Histologic Analyses 
After euthanasia, the lungs were inflated with 10% formalin via a tracheal cannula, 
removed from the thoracic cavity, fixed overnight in formalin and then paraffin embedded. 
Lung sections were stained with hematoxylin and eosin for routine histology and Masson's 
trichrome for evaluation of collagen deposition.  
7. Measurements of Lung Mechanics 
Mice were anesthetized after thoracic radiation with 70-90 mg/kg pentobarbital sodium, 
tracheostomized, and mechanically ventilated at a rate of 350 breaths/min, with a tidal 
volume of 6ml/kg, and positive end-expiratory pressure of 3-4 cmH2O using a computer-
controlled small-animal ventilator (Scireq, Montreal, Canada). Once ventilated, mice were 
paralyzed with 0.8 mg/kg pancuronium bromide. Using custom designed software 
(FlexiVent, Scireq), airway pressure, volume, and airflow measurement were recorded by 
using a precisely controlled piston during maneuvers to evaluate lung mechanics as 
previously described [157]. 
8. ELISA Analyses of  TGF-β1 
Quantitative ELISA measurements of total TGF-β protein levels from lung extracts of 
irradiated and control female mice were determined using the Promega TGF-β1 Emax® 
Immunoassay systems according to the company protocols. 
9. Flow Cytometry 
  Lungs were harvested from irradiated female mice at 0, 1, 4, 8, 12, 16, 20, 24 and 28 
weeks post-XRT. Excised whole lungs were minced and digested in RPMI with 5% FCS, 1 
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mg/ml collagenase A and 25 units/ml of DNAse for 1 hour. Red blood cells were lysed with 
ACK buffer, and nucleated cells were washed three times with PBS, layered on a 20% 
Percoll gradient and spun at 1500 x g for 30 minutes before resuspension in PBS with 2% 
FBS. Then resultant total mononuclear cells from both lungs were stained with PE- or FITC-
labeled monoclonal antibodies to murine CD45, CD3, CD4, CD8, F4/80, and Gr-1 
(Pharmingen, San Jose, CA ) and then analyzed on a FACScan with Cytomation software. 
II.C. Results 
1. Survival analysis of C57BL/6J Mice after Thoracic Irradiation  
C57BL/6J male mice received thoracic irradiation as a single dose of 14.5 Gy with a lead 
shield to exclude other body areas and then were monitored for up to 32 weeks. Premature 
death is defined as death before 32 weeks. Approximately half (48%) of irradiated WT mice 
died by 32 weeks after irradiation (Figure 2.1). End stage lung damage after radiation has 
both pneumonitis and fibrosis, also known as organizing alveolitis. Death appeared to be 
mostly due to chronic hypoxemia from poor diffusion of gas across fibrotic lung.   
2. Lung Hydroxyproline and Cross-linked Collagen is Increased after Irradiation 
Right lungs were harvested from the irradiated mice at 32 weeks after thoracic radiation. 
Hydroxyproline is a major component of the collagen and is found in few proteins other than 
collagen. Hydroxyproline content has been used as an indicator to determine collagen [158]. 
Therefore, we conducted hydroxyproline (HYP) assays of whole lungs to quantitate fibrosis. 
Pyridinoline (PYR) assays were performed to quantitate the cross-linked collagen. As shown 
in Table 2.1, the dry weight and hydroxyproline content of WT mouse right lungs increased 
(32%, p=0.018 and 35%, p<0.001) at 32 weeks post-irradiation, concurrent with the lung 
fibrosis seen in histology. Cross-linked collagen also increased at 32 weeks post-irradiation,  
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Figure 2.1 Survival analyses of irradiated WT mice by Sigmaplot 8.0. WT (n=39) animals 
received a single dose of 14.5 Gy of thoracic irradiation. Premature death was defined as 
death before 32 weeks post-radiation.  
 
 
Table 2.1 Lung dry weight, hydroxyproline (HYP) and pyridinoline (PYR) content after 
irradiation in WT mice  
Group Dry weight(mg) HYP(µg/right lung) PYR(µg/right lung) 
Control 23.56±1.29 232.15±29.07 1.047±0.13 
IR 31.19±2.02 312.15±34.93 1.267±0.22 
P value 0.018 <0.01 0.077 
Values shown are mean±SEM from 5~9 mice per group 
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although the increase did not reach statistical significance (p=0.077). 
3. Increased Gene Expression of Lung Collagen 1α 
Collagen 1 and collagen 3 are the major components of connective tissue in the lung and 
are mostly synthesized by fibroblasts [158]. Previous studies have shown that type I collagen 
gene expression increases in bleomycin-treated mouse lungs and is associated with increased 
TGF-β, a profibrotic cytokine [159, 160]. However, Type III collagen is the predominant 
type in granulation tissue. To investigate which type of collagen contributes to radiation lung 
fibrosis, lung collagen 1α1 and 3α1 mRNA in lung were measured using Commercial 
TaqMan gene expression assays. As shown in Figure 2.2, collagen 3α1 gene expression 
significantly increased at 3 weeks following irradiation and remained elevated through 32 
weeks post-irradiation. In contrast, there was no increase in collagen 1α1 gene expression. 
Therefore, type III collagen is predominant in radiation-induced lung fibrosis, while type I 
collagen predominates in bleomycin-induced lung fibrosis [160].  
4. No Increase in Lung Elastin 
Elastin is a major component of lung connective tissue. Increased elastin has been 
reported in the bleomycin and butylated hydroxytoluene models of lung fibrosis [161, 162]. 
However, we found no difference between irradiated mice and non-irradiated mice in the 
total amounts of elastin in the right lungs (Figure 2.3). 
5. Histologic Analyses 
As shown in Figure 2.4, some minor histologic changes occur in lungs at 8-12 weeks 
post-irradiation, including edema and mild inflammatory cell infiltration. Morphologic 
changes became more distinct at 24 weeks post-irradiation, including alveolar inflammatory 
cell accumulation, septal thickening and small, but distinguishable fibrotic foci. By 32 weeks 
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post-irradiation, the lungs of irradiated WT mice had septal thickening, diffuse inflammation, 
alveolar inflammatory cells (especially foamy macrophages), and patchy interstitial collagen 
deposition. In summary, the histologic characteristics of the lung responses to irradiation we 
observed in our model were consistent with those seen in other studies. 
6. Diminished Lung Function after Thoracic Irradiation 
To investigate lung function after thoracic radiation-induced lung injury, anesthetized 
mice were subjected to lung function tests while ventilated as described previously. 
Decreased compliance and increased tissue elastance are expected in radiation-induced 
fibrotic lung. Consistent with this expectation, the static compliance of the irradiated WT 
mice at 20 weeks and 32 weeks post-irradiation have a decrease of 7.7% (p=0.007) and 24% 
(p<0.0001), respectively. The tissue elastance of the irradiated WT mice at 20 weeks and 32 
weeks post-irradiation have an increase of 14% (p=0.007) and 82% (p<0.0001), respectively. 
(Figure 2.5). 
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Figure 2.2 Increased lung collagen 3α1 gene expression in irradiated WT mice. Lung total 
RNA from non-irradiated control and irradiated WT mice was analyzed for collagen 1α1 and 
3α1 mRNA expression by real-time RT-PCR. Collagen 1α1 and 3α1 gene expression is 
relative to Gus expression as indicated in Materials and Methods, and normalized to the 
levels in control mice. Values shown represent mean±SD from 5~9 mice per group. * p < 
0.05, compared to WT non-irradiated control.  
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Figure 2.3 Lung elastin is not increased in irradiated WT mice. Mouse right lungs were 
homogenized in 2ml 1xPBS and incubated in 0.5ml 1M acetic acid containing 6mg/ml pepsin 
for 24h at room temperature with stirring (1500rpm). Supernatants were obtained by 
centrifugation for 30 minutes at 5,000xg, 4 oC, and then analyzed using the Fastin elastin 
assay according to the manufacturer’s protocol (Biocolar CO., County Antrim, UK).  
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Figure 2.4 Changes in lung histology after irradiation in WT mice. Lungs were harvested at 
0, 4, 8, 16, and 24 and 32 weeks post-irradiation and inflated with 10% formalin via a 
tracheal cannula, then removed from the thoracic cavity, and fixed overnight in formalin. 
Lung sections were stained with hematoxylin-eosin for routine histology (right panel) and 
Masson's trichrome for evaluation of collagen deposition (left panel).  
Control 
4 weeks 
8 weeks 
16 weeks 
24 weeks 
32 weeks 
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Figure 2.5  Analysis of lung mechanics demonstrates that irradiated WT mice had 
diminished lung function after thoracic radiation. Lung mechanics were measured by 
FlexiVent in anesthetized, paralyzed, and mechanically ventilated mice at 20 and 32 weeks 
post thoracic irradiation. A. Static compliance (Cst) was determined by fitting the Salazar-
Knowles equation to pressure-volume curves. B. Tissue Elastance (H) was determined by 
applying prime wave impedance values to the constant phase model. Values shown are 
mean±SEM of 6-9 mice per group. *p < 0.05, compared with non-irradiated controls. 
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7. Increased TGF-beta1 in lung after Thoracic Irradiation 
 TGF-β1 protein increased in the lungs of the irradiated female WT mice at 16, 24 and 28 
weeks post-irradiation (Figure 2.6). This upregulation of TGF-β1 preceded the fibrosis,  
suggesting a pathogenic role in radiation fibrosis, similar to that seen in other fibrosis models 
[40, 163]. 
8. Flow cytometric analyses of lung inflammatory infiltration  
To better understand the cellular mediators involved in radiation lung injury, we analyzed 
the pulmonary inflammatory cell infiltrates in irradiated female mice over time. The data 
shown represents the average cell numbers in the right lung. As Figure 2.7 shows, the lung 
CD45+ leukocytes decreased within the first week after irradiation, and gradually returned to 
the basal level by 4 weeks, likely reflecting the initial apoptosis induced in resident cells by 
radiation. By 12 weeks, inflammatory cell infiltrates increased, peaking at 24-28 weeks. 
CD4+ and CD8+ T cells returned to the basal level at 8 weeks and remained elevated above 
the basal levels, thereafter consistent with expansion on ongoing recruitment. Analyses of 
F4/80+ macrophages showed increases at 4 to 16 weeks, with a drop at 20 weeks, and then 
dramatically increasing again at 24 weeks. Interestingly, both the early and late peaks in 
pulmonary macrophages preceded the peaks in TGF-β1 levels (Figure 2.6&2.7D), 
suggesting that the macrophage may be important source of this profibrotic cytokine, as has 
been reported by others [37, 40, 163]. Interestingly, neutrophilic inflammation, clearly a 
hallmark of many acute lung injury models, does not appear be a significant factor in this 
model (Figure 2.7E). These data show that inflammatory cell infiltration begins at 4 weeks 
after XRT and has second higher and more prolonged peak beginning at 24-28 weeks. As we 
know from the histologic analyses, radiation-induced fibrosis becomes overtly apparent after  
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Figure 2.6 Increased levels of total TGF-β  protein in the lungs of irradiated female WT 
mice. TGF-β in left lungs was measured by ELISA (Promega) after 14.5 Gy of thoracic 
irradiation. Each bar represents 6-13 animals at each time point. * p < 0.05 compared to the 
non-irradiated control mice. 
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.7 Analyses of the inflammatory cells in the lungs of female WT mice after thoracic 
n. A. total leukocytes (CD45+); B. CD4+ T cells; C. CD8+ T cells; D. macrophage 
80+) ; E. neutrophils * P < 0.05, compared to the non-irradiated control mice. 
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28 weeks post-irradiation. Therefore, in our model we divide radiation-induced lung injury into 
two phases: pneumonitis (4-20 weeks) and fibrosis (>20weeks). 
Summary of our model of radiation-induced lung injury 
• Pneumonitis starts around 4-12 weeks actually 4-12 based. 
• Marked infiltration of leukocytes, CD4+ T cells, CD8+ T cells and macrophages.   
• Fibrosis becomes histologicaly apparent at 24-32 weeks with patchy foci of 
inflammatory cells and collagen deposition. 
• Increased alveolar septal wall thickness; coincident with increased lung TGF-β protein. 
• Decreased lung compliance and increased tissue elastance. 
 
III. Macrophage inflammatory protein-1 alpha (MIP-1α/CCL3) is a mediator of 
radiation-induced lung injury 
III.A. Abstract 
Thoracic radiation is a common treatment for several types of cancer. Although 
patients often benefit from this treatment, it can also lead to pneumonitis and pulmonary 
fibrosis. Since MIP-1α (CCL3) functions in several types of pathogen-associated 
pneumonitis [138, 139], we reasoned that the cellular and molecular events linking thoracic 
radiation to pulmonary fibrosis might also involve CCL3. Thus, we used our model of a 
single dose thoracic radiation to study the role of CCL3 as a mediator of radiation lung 
injury.  
Initially, we determined that CCL3 expression increased from baseline levels 
approximately 4 weeks after irradiation, declined to baseline levels by 8 weeks, and 
increased again at 20 weeks post-irradiation. This late increase in CCL3 expression coincided 
with a sharp increase in TGF-β1 expression, and preceded the death of these C57BL/6J mice 
from their radiation-induced injuries. Compared to wild type C57BL/6J mice, congenic, 
aged-matched CCL3-deficient mice had longer mean survival times, diminished 
inflammation, less collagen deposition and preserved lung function. In addition, CCL3-
deficient mice did not display the increased TGF-β1 expression seen in C57BL/6J mice 
immediately prior to the onset of fibrosis. Taken together, these data demonstrate that CCL3 
functions in the pneumonitis, TGF-β production and pulmonary fibrosis caused by thoracic 
radiation. 
III.B. Introduction 
 Cell recruitment to injured tissue is an essential component of inflammation, which is 
largely orchestrated by a family of chemotactic cytokines known as chemokines [164, 165].  
The chemokine CCL3 is secreted from various leukocytes, including T lymphocytes and 
activated macrophages, and acts to recruit CCR1-expressing and/or CCR5-expressing 
leukocytes, e.g., monocytes, dendritic cells, natural killer cells and T lymphocytes [140]. 
CCL3 can mediate pulmonary inflammation in response to a variety of pathogens, including 
influenza virus [166], Cryptococcus neoformans [167], Apergillus fumigatus [168], 
schistosome mansoni egg [147] and graft versus host disease (GVHD) [169]. Johntson 
reported a strong correlation between elevated CCL3 and development of late effects in 
radiation-induced fibrosis-sensitive mice [148]. Together, these observations suggest that 
CCL3 might be an important mediator in radiation-induced pneumonitis and fibrosis. Indeed, 
we show here that CCL3 expression increases in the lungs of irradiated mice, and that mice 
lacking this chemokine are protected from the marked pulmonary inflammation, fibrosis, and 
high mortality seen in irradiated wild type mice. 
III.C. Materials and Methods 
1. Cell Cultures 
 MRC5 lung fibroblast and SKLu-1 lung adenocarcinoma cell lines were irradiated with 
a single dose of 5 Gy. Culture supernatants were collected twelve hours later for CCL3 
protein quantitation by ELISA (QuantikineTM, R&D, Minneapolis, MN). 
2. Animals 
  All animal studies were performed under approval by the IACUC at the University of 
North Carolina at Chapel Hill. Homozygous mice (C57BL6-Scya3tm1unc), deficient in the 
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production of the chemokine CCL3, were generated by gene targeting [166]. Wild-type 
C57BL6 mice were purchased from Jackson Laboratories. All mice were housed in 
microisolator cages maintained in a specific pathogen-free environment. Lungs were 
harvested from mice after sedation with 2.5% Avertin, injection with 100 units of heparin to 
prevent clotting, and perfusion with 10 ml of PBS. Animals were then euthanized and lungs 
were harvested at various time points up to 32 weeks post-irradiation. 
3. Irradiation 
  Anesthetized mice, 8-14 weeks of the age, were immobilized with a lead shield that 
protected the mouse body except for the thoracic cavity. Animals were irradiated with a dose 
of 14.5 Gy from a cesium source ((J. L. Shepherd & Associates, San Fernando, CA, USA) at 
a dose rate of 1.65 Gy/min. 
4. ELISA  analyses of TGF-β1 
Quantitative ELISA measurements of CCL3 and active TGF-β1 protein levels from lung 
homogenates were determined using the QuantikineTM CCL3 and the Promega TGF-β1 
Emax® Immunoassay systems according to the company protocols.  
5. Quantification of Lung Hydroxyproline 
  After harvesting, lung tissue was acid digested and then hydroxyproline content was 
analyzed as described [170]. 
6. Flow Cytometry 
Flow cytometric analyses of lung leukocytes were performed as described in Chapter II, 
using PE- or FITC-labeled monoclonal antibodies to murine CD3, CD4, CD8, CD19, B220, 
F4/80, and Gr-1(Pharmingen) and then analyzed on a FACScan with Cytomation software. 
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7. Histologic Analyses 
  Mice were sacrificed for histologic analyses at various times post-irradiation. After 
euthanasia, lungs were expanded and fixed by intra-tracheal instillation of 4% 
paraformaldehyde. Histologic sections were stained with hematoxylin and eosin for 
inflammation or Masson’s Trichrome stains for interstitial and alveolar collagen. Lung 
sections were scored on a scale of 0-4+ for pneumonitis and fibrosis by a pathologist blinded 
to the sample genotype. 
8. Antinuclear Antibody Assay 
Serum specimens were prepared from control non-irradiated mice and irradiated mice at 
32 weeks post-irradiation. Antinuclear antibody assays were performed according to the 
manufacturer’s protocol (Alpha Diagnostic International Inc., San Antonio, TX).  
9. Statistical Analyses 
 Differences between WT and CCL3-/- animals were examined for statistical significance 
by student’s t-tests or by Mann-Whitney tests using SigmaStat software.  
III.D. Results 
1. Irradiation induces CCL3 expression in lung-derived cells in vitro 
To determine whether CCL3 expression can be directly induced by radiation, we 
irradiated two lung-derived cell lines, MRC5 normal lung fibroblasts and SKLu-1 lung 
adenocarcinoma cells, with 5 Gy. Although not detectable (<1.5 pg/ml) prior to irradiation, 
CCL3 production increased significantly in both the MRC5 (5.22 pg/ml) and SKLu-1 (8.12 
pg/ml) cell lines after irradiation (Table 3.1). The induction of CCL3 production in both 
normal and malignant lung-derived cell lines suggests that this chemokine might also be 
induced in the lungs of irradiated mice. 
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2. CCL3 was  induced in the lungs of irradiated mice 
We next investigated whether CCL3 was induced in vivo by thoracic irradiation.  
C57BL/6J mice were irradiated (14.5 Gy) and euthanized at various time points thereafter for 
analysis of CCL3 production in the lung (Figure 3.1). Surprisingly, CCL3 levels declined 
during the first few days post-irradiation (possibly due to the death of chemokine-producing 
cells) and by day 5 CCL3 levels was significantly lower (about 4-fold) than pre-irradiation 
levels. By two weeks CCL3 levels began recovering to pre-irradiation levels, followed by a 
peak at four weeks post-irradiation (2-fold increase). CCL3 levels then decreased over the 8-
20 week period, except for the second peak at 20 wks. This biphasic pattern correlates well 
with the biphasic infiltration of inflammatory cells we noted over this time period (Figure 
2.7A). 
3. CCL3 -/- mice have improved survival after receiving thoracic radiation 
We next examined the relevance of CCL3 expression to radiation-induced lung injury by 
comparing the responses of irradiated wild type and CCL3-deficient mice. WT and CCL3-
deficient mice received a single dose (14.5 Gy) of thoracic irradiation. Approximately 52% 
of the WT mice receiving 14.5 Gy died by 32 weeks post-irradiation (Figure 3.2). In marked 
contrast, only 16% of the CCL3-deficient mice died following this dose of irradiation. These 
dramatic differences demonstrate that CCL3 functions in events leading to thoracic radiation-
induced premature death. 
4. CCL3-deficient mice have decreased fibrosis after lung irradiation  
To determine whether the difference in mortality between WT and CCL3-deficient 
animals was related to fibrosis, mice were sacrificed at 32 weeks post-irradiation and their 
lungs were examined for fibrosis. The amount of collagen in the right lung was determined  
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Table 3.1 CCL3 Expression from Lung Cell Lines* 
 
 
 
 
 
133.8 pg/ml 8.1 pg/ml< 1.5 pg/mlSkLu Lung 
73.9 pg/ml 5.2 pg/ml< 1.5 pg/ml
5 Gy Irradiation
MRC5 Lung Fibroblast 
TNF-α (+ control) ControlCell Line
*Confluent monolayer of MRC5 normal lung fibroblasts and SkLu lung adenocarcinoma 
cells were irradiated with 5 Gy. Twelve hours later, cell supernatants were harvested and 
assayed for CCL3 content by ELISA. 
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Figure 3.1 Thoracic irradiation-induced production of CCL3 in vivo. Wild-type mouse 
thoracic cavities were irradiated with 14.5 Gy. At the indicated times after irradiation, whole 
lungs were harvested for analysis of CCL3 content by ELISA. * p values were < 0.05 for the 
following time points compared to the sham controls: day 5, wk 4, and wk 20 (n = 3-6 mice 
per time point).  
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Figure 3.2 CCL3-/- mice have improved survival after thoracic radiation. WT and CCL3-
deficient mice received 14.5 Gy thoracic irradiation and post-irradiation survival at 32 weeks 
was analyzed by Sigmaplot 8.0. *p<0.001, compared with irradiated WT mice. 
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by measurement of hydroxyproline content. As expected, there was a significant increase in 
lung hydroxyproline contents in WT mice after radiation (Figure 3.3). Lung hydroxyproline 
contents of irradiated CCL3-deficient mice were higher than in non-irradiated CCL3-
deficient mice, but were significantly lower than irradiated WT mice. Hematoxylin and eosin 
and Masson's Trichrome staining of lung sections were used to examine lung sections for 
inflammation and fibrosis. As previously described for this model, marked alterations were 
observed in WT mice at 32 weeks following thoracic irradiation, i.e., inflammatory and 
fibrotic foci, increased septal cellularity and thickness, and increased collagen deposition 
(Figure 3.4A, B and C). In contrast, CCL3-/- mice have only rare tiny foci of inflammation or 
fibrosis. 
5. CCL3-/- mice have decreased TGF-β1 production after thoracic irradiation   
An association between TGF-β1 production and pulmonary fibrosis is well documented 
[171].  We therefore compared the levels of this protein in C57BL/6J and CCL3-deficient 
animals at various time points after 14.5 Gy of thoracic irradiation (Figure 3.5). It is notable 
that at 3 weeks post-irradiation, TGF-β1 protein levels were slightly increased to similar 
levels in both WT and CCL3-deficient animals, but returned to baseline levels shortly 
thereafter in WT mice and below baseline in CCL3-defficient mice. This data suggests that 
this early increase in TGF-β1 may be not crucial to the development of fibrosis in WT 
animals, although it did occur just prior to the initial influx of inflammatory cells. In contrast, 
at the time when fibrosis is beginning (> 16 wks), TGF-β1 levels progressively increase to 
above the baseline in the WT lungs, suggesting that late TGF-β1 production is a key 
mediator of the fibrosis phenotype seen in these animals. CCL3 has been reported to induce 
TGF-β production from macrophages which accumulated in the lungs of irradiated WT mice  
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Figure 3.3 CCL3-deficient mice have much less lung fibrosis after thoracic irradiation. 
Right lungs from WT and CCL3-deficient mice were harvested 32 weeks after radiation and 
hydroxyproline assays were conducted. non-IR=non-irradiated control; IR=irradiated. 
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Figure 3.4 Histologic analyses showed that CCL3-deficient mice had less lung 
inflammation and fibrosis after irradiation. Lungs harvested 32 weeks post-irradiation and 
stained with Hematoxylin-eosin (H&E) or Masson's trichrome (MT). A. Whole sections of 
MT stained lungs. B. H&E stained section at 20x magnification. C. MT stained sections at 
20x magnification. Inflammatory and fibrotic foci were seen in irradiated WT, but not in 
CCL3-/- mice. 
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Figure 3.5 Quantitative analysis of lung totalTGF-β1 protein by ELISA after 
irradiation. Each bar represents 3-5 animals of each genotype. Data from control (non-
irradiated) mice of each genotype from various time points were pooled and are shown at day 
0 (controls). * P values < 0.05 at wk 3 and wk 20 for the WT mice compared to the non-
irradiated WT mice and at 3 wks for the CCL3-deficient mice compared to the non-irradiated 
CCL3-deficient mice. 
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during the fibrotic phase [172]. It probably explains why we observed low TGF-β1 levels at 
fibrotic phase in CCL3-deficient mice. In conclusion, TGF-β1 protein upregulation preceded 
the radiation-induced pulmonary fibrosis, suggesting a pathogenetic role in the development 
of radiation fibrosis. 
6. CCL3-deficient mice have decreased pneumonitis after lung irradiation 
CCL3 functions in several models of pulmonary inflammation [138, 139]. We therefore 
investigated whether the decreased mortality and collagen production seen in the irradiated 
CCL3-deficient mice was also associated with a decrease in radiation-induced pneumonitis.  
Mice were harvested up to 32 weeks post-irradiation and their lungs prepared and sectioned 
for histologic staining and scored in a blinded fashion for inflammation and fibrosis. Each 
section was assigned a score between 0 and 4, based on the extent of inflammation (Table 
3.2). Irradiated CCL3-deficient mice have a statistically significant decrease in pneumonitis 
as well as fibrotic foci compared with irradiated WT mice. Thus, the decreased mortality and 
collagen production in CCL3-deficient mice is associated with the reduced inflammation.  
7. Flow cytometric analyses of pulmonary inflammatory cell  infiltration 
To better understand the inflammatory events following thoracic irradiation, cells were 
prepared from the lungs of C57BL/6J and CCL3-deficient mice at various times post-
irradiation and analyzed by flow cytometry. The prepared cells were stained with 
fluorescent-labeled antibodies against the cell surface markers CD3, CD4, CD8, CD19, 
B220, F4/80, and Gr-1. 
The greatest differences between irradiated wild type and CCL3-deficient mice were the 
numbers of lung CD4+ T cells and monocytes/macrophages (Figure 3.6). In both WT and 
CCL3-deficient mice, the number of CD4+ T cells decreased during the first few weeks after 
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Table 3.2 Histologic analyses of lungs after irradiation 
 
Genotype Pneumonitis Fibrosis 
WT 1.7 ± 0.33 ++ 
CCL3-/- 0.27 ±  0.14* negligible 
* p = 0.001, compared to WT.      
The extent of parenchymal inflammation was determined by averaging the scores (0 to 4, 
representing no, <25%, 25-50%, 50-75%, and >75% involvement) from 10 high power 
fields. Fibrosis was scored by examination of 10 high power fields for fibrotic foci as 
identified with Masson’s1 Trichrome staining. 
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irradiation due to depletion of cells by radiation, and progressively increased to the basal 
level by 12 weeks. By 20 weeks, the number of lung CD4+ T cells in irradiated WT mice was 
significantly greater than the basal level and remained elevated during the following period. 
In contrast, the number of lung CD4+ T cells in irradiated CCL3-deficient mice was never 
higher than the basal level. Analyses of F4/80+ macrophages showed a biphasic pattern but 
significant increases were only seen in irradiated WT mice at 12 and 32 weeks post-
irradiation (Figure 3.6D). Consistently, we also saw numerous large foamy macrophages in 
histologic sections of WT lungs at 32 week post-irradiation, but not in CCL3-deficient mice 
(Figure 3.6E). The pattern of macrophage accumulation correlates with the production of 
TGF-β1 and indeed the second peak of macrophage infiltration occurs when the fibrosis 
phase starts.  
Neutrophilic inflammation, clearly a hallmark of many acute lung injury models, does 
not appear to be a significant factor in this model since the patterns of neutrophil infiltration 
into the lung of irradiated WT and CCL3-deficient mice were similar (data not shown). 
Taken together, these data suggest that macrophages and CD4+ T lymphocytes may be 
the most important cellular mediators of radiation pneumonitis and fibrosis. Lastly, analyses 
of peripheral white blood cell counts did not reveal marked differences between C57BL/6J 
and CCL3-deficient mice, suggesting that CCL3 likely functioned locally in recruiting cells 
to the lung, rather than as a result of systemic inflammation. 
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Figure 3.6 CCL3-deficient mice have fewer lung inflammatory cells after irradiation. 
The lungs were harvested and minced at 0,1,4,12,20 and 32 weeks post-irradiation. After 
enzymatic digestion, the cells were stained with FITC, PE, PerCP, or APC labeled 
monoclonal antibodies to murine CD45, CD3, CD4, CD8, and F4/80 (Pharmingen). A. 
CD45+ leukocytes, B. CD4+ T cells, C. CD8+ T cells, D. Macrophage, and E. Arrow 
indicates increased foamy macrophages in H&E stained sections of irradiated WT mouse 
lungs, but not seen in nonirradiated WT and irradiated CCL3-deficient mice. Each bar 
represents 3-8 animals of each genotype. 
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8. Antinuclear autoantibody and B cell infiltration 
We tested for the relevance of autoimmune phenomena in our model by analyzing serum 
levels of antinuclear autoantibodies (ANAs) by ELISA. Serum ANAs were elevated 
significantly at 32 weeks post-irradiation in WT mice, however, there was no change seen in 
irradiated CCL3-deficient mice (Figure 3.7A). In WT animals, there was also significant 
infiltration of B cells into lung at 12 and 20 weeks post-irradiation that, again, was not 
observed in CCL3-deficient mice (Figure 3.7B). Taken together, these data suggest that after 
the initial oxidative damage and cytokine induction, post-irradiation lung inflammation and 
fibrosis may occur at least in part as an autoimmune disease. 
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Figure 3.7 Evidence for autoimmune processes in radiation-induced lung injury. A. 
Serum antinuclear antibody measured by ELISA. B. B cell infiltration in lungs after 
irradiation. * p < 0.05, for irradiated mouse lung compared to nonirradiated control. 
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III.E. Discussion 
The work reported here was begun to gain a better understanding of the cellular and 
molecular events leading from thoracic radiation to pulmonary fibrosis. We showed that 
thoracic radiation of mice induces the pulmonary expression of CCL3 and that mice lacking 
this chemokine have diminished inflammation, less collagen deposition and longer mean 
survival times than irradiated C57BL/6J mice. Our finding that radiation can also induce 
CCL3 production in cultured cell lines suggests chemokine production can be an immediate 
and locally residual response to radiation.  In irradiated mice, pulmonary expression of CCL3 
was highest at 4 weeks and 20 weeks post-irradiation, which precedes the influx of 
inflammatory cells and fibrotic stage. There was basically no increase over basal levels of 
macrophages, CD4+ T cells, CD8+ T cells and B cells in CCL3-deficient mice compared to 
WT mice, whereas WT mice showed significant increases in all of these types over basal 
levels beginning at 12 weeks post-irradiation. These findings suggest that CCL3 production 
is required for recruitment of macrophages, CD4+ T cells, CD8+ T cells and B cells into 
irradiated lungs. 
In addition to the significant infiltrations of B cells in WT mice after thoracic 
irradiation, increased serum levels of antinuclear autoantibodies were seen in irradiated WT 
mice, but not in CCL3-deficient mice. These findings suggest autoimmunity may contribute 
to the development of radiation-induced lung injury.  
 Among the cytokines known to participate in fibrosis, TGF-β1 is probably the-best 
studied. TGF-β1 is upregulated in the lung parenchyma of patients with pulmonary fibrosis 
[173], increases the production of collagen and other extracellular matrix components [174-
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176], and regulates the expression of other genes associated with ECM degradation and 
proteolysis. Indeed, a common feature among many models of pulmonary fibrosis is the 
upregulation of TGF-β1 expression in the lung.  Our finding that the second increase in TGF-
β1 expression requires CCL3, suggests that it either acts directly to induce production of 
TGF-β1 in resident lung cells, or recruits TGF-β1-expressing cells to the lung. One obvious 
candidate is the macrophage, which can be recruited by CCL3, and is among the wide variety 
of cells that can produce TGF-β1. Not surprisingly, the pattern of macrophage infiltration we 
saw in irradiated WT lung well correlates with the increased production of TGF-β1. 
 In summary, our results demonstrate that CCL3 production is induced by thoracic 
radiation, and that this production leads to enhanced pneumonitis, TGF-β1 production and 
ultimately, death of the irradiated mice from pulmonary fibrosis. Although additional studies 
are required to determine the impact of individual CCL3-dependent cellular and molecular 
events on fibrosis, our findings suggest that the CCL3 signaling pathways might lead to 
novel therapies to treat individuals at risk for radiation-induced pulmonary fibrosis. 
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IV. C-C chemokine receptor 1 mediates radiation-induced pulmonary injury  
IV.A. Abstract 
Radiation-induced lung injury is a common adverse effect in thoracic radiation-
treated patients. We previously found that CCL3 deficiency significantly protects mice from 
developing radiation-induced pneumonitis and lung fibrosis. To determine which CCL3 
receptor is crucial in mediating radiation-induced lung injury, C-C chemokine receptor 1 
(CCR1)-deficient and C-C chemokine receptor 5 (CCR5)-deficient mice were irradiated with 
a single dose of 14.5 Gy to the thorax. Our present studies show that CCR1-deficient, but not 
CCR5-deficient, mice have radio-protected phenotype. In fact, the CCR5-deficient mice have 
worse pneumonitis and fibrosis than wild-type (WT) mice after thoracic radiation. In contrast, 
when compared to WT mice, irradiated CCR1-deficient mice have improved survival, 
virtually no pneumonitis or fibrosis, and preserved lung function. We also show that CCR1-
deficient mice have less inflammatory infiltration after thoracic irradiation. Compared with 
irradiated WT mice, irradiated CCR1-deficient mice have lower levels of TGF-β1 protein 
and lower levels of mRNA expression of other profibrotic cytokines, IL-4 and IL-13. 
Furthermore, mice treated with CCR1 inhibitor (BX471) show similar protection from 
pulmonary fibrosis and preserved lung function after thoracic radiation. Therefore, the fact 
that genetically generated CCR1 deficiency and CCR1 blockade with a specific antagonist 
had the same effect on pulmonary inflammation and fibrosis after thoracic irradiation 
provides powerful evidence that CCR1 is a promising target for reducing radiation-induced 
injury.  
III.B. Introduction 
In spite of intensive research addressing radiation pneumopathy, there is no 
universally accepted reliable model. Compared with other lung fibrosis models such as 
bleomycin-induced fibrosis, radiation-induced lung fibrosis has some unique characteristics. 
Radiation-induced lung fibrosis has an insidious onset and is irreversible, which indicates 
that its pathogenesis is at least in part different from other lung fibrosis models. Therefore, 
evidence from other lung fibrosis models can not be simply extrapolated to radiation 
pneumopathy. 
We have recently found that in comparison to WT mice, CCL3-deficient animals are 
significantly protected from developing radiation-induced lung pneumonitis and fibrosis. 
These findings suggest that chemokines and their receptors might represent excellent 
molecular therapeutic targets for reducing or eliminating radiation-induced pneumonitis and 
subsequent fibrosis. Here, we specifically studied the CCL3 receptors, CCR1 and CCR5, for 
their potential roles in development of radiation-induced lung injury. In this study, we 
demonstrated that CCR1, induced by thoracic irradiation, accompanied the recruitment and 
activation of lymphocytes and macrophages and the subsequent cytokine production in the 
development of radiation pneumonitis and fibrosis. Furthermore, we show that the CCR1 
inhibitor, BX471, ameliorates the progressive pneumonitis and fibrosis induced by thoracic 
irradiation. 
IV.C. Materials and Methods 
1. Mice 
All animal studies were performed under approval by the IACUC at the University of 
North Carolina at Chapel Hill. Wild-type C57BL6 mice were purchased from Jackson 
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Laboratories. CCR1-/- and CCR5-/- C57BL6 mice in were obtained from Dr. Nobuyo Maeda 
and bred according to DLAM policies. All mice were housed in microisolator cages 
maintained in a specific pathogen-free environment. All mice used in this study were male 
and age-matched. 
2. Thoracic irradiation 
 Animals were irradiated with a singled dose of 14.5 Gy as described in chapter II.  
3. Histopathology and morphometric analyses 
After euthanasia, the lungs were inflated with 10% formalin via a tracheal cannula, 
removed from the thoracic cavity, fixed overnight in formalin and then paraffin embedded. 
Lung sections were stained with hematoxylin and eosin for routine histology and Masson's 
trichrome for evaluation of collagen deposition. Histologic data were quantitated by digital 
imaging of the hematoxylin and eosin stained sections. While blinded to genotype and 
treatment, we captured ten images (5x) of representative areas of each lung lobe and then 
analyzed each image for septal thickening due to increased inflammatory cell infiltration, 
extracellular matrix deposition, and fibroblasts proliferation. With the software ImageJ 
(National Institutes of Health), the threshold was set to count the number of pixels contained 
within areas of the digital images. The threshold number of pixels was then divided by the 
total number of pixels in the entire image and multiplied by 100 to generate a percentage of 
area affected by fibrosis and inflammation. 
4. Hydroxyproline assay 
Lung hydroxyproline content was measured as described in Chapter II.  
5. Measurements of lung mechanics 
Lung compliance and tissue elastance were evaluated as described Chapter II. 
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6. Flow Cytometry 
Flow cytometric analyses of lung leukocytes were performed as described in Chapter II. 
7. Gene expression analyses  
Gene expression analyses of lung homogenates were performed as described in Chapter 
II, page 41.  
8. ELISA Analyses 
Quantitative ELISA measurement of TGF-β protein levels from lung extracts was 
performed using the Promega TGF-β1 Emax® Immunoassay systems according to the 
company protocols. 
9. Administration of the CCR1 Inhibitor BX-471 
BX-471 was dissolved in a 40% Cyclodextrin vehicle (Sigma). BX-471 treatment was 
initiated 4 weeks after irradiation based on our previous data showing that CCR1 gene 
expression started to increase at this time point. Irradiated WT mice received twice daily 
subcutaneous treatments with BX-471 for a total of 4 weeks at a dose of 30 mg/Kg of body 
weight.  One group of irradiated mice was given BX-471 treatment for 4 weeks. A control 
group of irradiated mice were given vehicle only twice daily for 4 weeks. A second control 
group was the nonirradiated age-matched mice. Mice were closely monitored daily and were 
euthanized and analyzed at 32 weeks after irradiation. 
10. Statistical Analyses 
Two-tailed Student’s t-tests were performed to compare results of hydroxyproline 
content, histological analysis, function test, flow cytometry analysis, and RT-PCR. A p value 
≤ 0.05 was considered significant.  
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IV.D. Results 
1. CCR1 and CCR5 expression in the lung after thoracic irradiation 
To characterize the patterns of CCR1 and CCR5 expression in the lung after thoracic 
irradiation, WT mice were irradiated and their lungs were harvested at 1, 4, 12, 20 and 32 
weeks following irradiation. CCR1 and CCR5 expression in the lung was analyzed by 
quantitative RT-PCR. CCR1 expression began to increase significantly at 4 weeks following 
irradiation, had a 5-  
fold elevation at 20 weeks and remained elevated through 32 weeks (Figure 4.1). The 
expression of CCR5 was significantly increased at 12 weeks following irradiation and 
remained elevated through 32 weeks. It is noted that the increase in CCR1 expression at 4 
and 20 weeks coincides very well with the increases in CCL3, suggesting that CCL3 may 
directly lead to CCR1-expressing cell accumulation. 
2. CCR1-, but not CCR5-deficient, mice have a protected phenotype from radiation-
induced lung injury 
In order to determine whether CCR1-deficient or CCR5-deficient mice were protected 
from radiation-induced lung injury, these mice received thoracic irradiation at a single dose 
of 14.5 Gy and were monitored for up to 32 weeks. Premature death is defined as death 
before 32 weeks. In comparison with the WT mice, CCR1-deficient mice had a significantly 
improved survival rate (Figure 4.2A). In contrast, there was no difference in survival rate 
between WT and CCR5-deficient mice after radiation.  
In order to assess lung fibrosis, the amount of collagen in the right lung was determined 
by measurement of hydroxyproline. As expected, there was a significant increase in the lung 
hydroxyproline content in the irradiated WT (Figure 4.2B); however, this increase was not 
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seen in irradiated CCR1-/- mice. In contrast, the lung hydroxyproline content of irradiated 
CCR5-/- mice was even higher (15%) than that seen in the irradiated WT mice. Hematoxylin 
and eosin and Masson's Trichrome staining of lung sections was used to assess lung 
inflammation and fibrosis. As previously described, we observed inflammatory and fibrotic 
foci, increased septal cellularity and thickness, inflammatory cell infiltration and increased 
collagen deposition in WT mice at 32 weeks post-irradiation (Figure 4.3). These histologic 
changes were even more profound in the irradiated CCR5-/- mice. In contrast, CCR1-/- mice 
had virtually no any foci of inflammation or fibrosis.  The digital imaging analyses showing 
that when compared with non-irradiated controls, both the irradiated WT and CCR5-/-, but 
not CCR1-/-, mice had increased septal thickening is also consistent with the hydroxyproline 
data (Figure 4.3D). 
3. CCR1-deficient mice have preserved lung function in response to thoracic 
irradiation 
In order to evaluate alterations of lung mechanics in CCR1-/-, and CCR5-/-, we used a 
computer-controlled small-animal ventilator. Decreases in compliance and increases in 
elastance were expected in radiation-induced fibrotic lung. Consistent with this expectation, 
the irradiated WT mice showed a significant decrease in static compliance and a significant 
increase in tissue elastance compared with non-irradiated control mice (Figure 4.4). Similar 
changes in compliance and tissue elastance were observed in the irradiated CCR5-/- mice. 
However, the static compliance of irradiated CCR5-/- mice was significantly lower than that 
of the irradiated WT mice. Neither a decrease in static compliance nor an increase in tissue 
elastance was observed in the irradiated CCR1-/- mice. As expected, based on lung histology,  
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Figure 4.1 Increased CCR1 and CCR5 mRNA expression in the lung after thoracic 
irradiation. Lung total RNA from non-irradiated control and irradiated WT mice was 
analyzed for CCR1 and CCR5 mRNA expression by real-time RT-PCR. Levels of mRNA 
expression of CCR1 and CCR5 were expressed relative to Gusb mRNA expression as 
indicated in Materials and Methods. CCR1 and CCR5 mRNA expression normalized to that 
of the non-irradiated controls. Values shown represent means±SD from 5~9 mice per group. 
* p < 0.05, compared with WT non-irradiated control.  
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Figure 4.2 CCR1-, but not CCR5-deficient, mice have a radio-protected phenotype. A. 
Survival curves at 32 weeks post-irradiation by Sigmaplot 8.0 showed CCR1-/-, but not 
CCR5-/- mice have better survival than irradiated WT mice. WT, CCR1-deficient, and CCR5-
deficient mice received thoracic irradiation as a single dose of 14.5 Gy. * p < 0.01.  B. 
Hydroxyproline content of right lungs of non-irradiated control and irradiated mice 32 weeks 
post-irradiation. nonIR, nonirradiated controls. IR, irradiated.   
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Figure 4.3 Histologic analyses show that CCR1-deficient, but not CCR5-deficient, mice 
have radio-protected phenotype. WT, CCR1-/- and CCR5 -/- mice received a single dose of 
14.5 Gy thoracic irradiation. Lungs were harvested at 32 weeks post-irradiation and stained 
with Hematoxylin&eosin (H&E) or Masson's trichrome (MT). A. Whole sections of MT 
stained lungs: inflammatory and fibrotic foci in irradiated WT and CCR5-/- mice, but not in 
CCR1-/- mice; arrows indicate areas of inflammation and fibrosis. B. H&E staining: areas of 
inflammation and fibrosis are seen in the lungs of the irradiated WT and CCR5 -/- mice, but 
not CCR1 -/- mice. C. MT staining: Collagen deposition is seen in the lungs of irradiated WT 
and CCR5 -/- mice but not CCR1 -/- mice. D. Quantitative measurement of lung tissue 
abnormalities by morphometric analysis of lung sections. Ten 5x images of each lung section 
were analyzed to quantify septal thickening as an indication of lung inflammation and 
fibrosis. Values shown are means±SEM of 4-8 lung sections per group. * p < 0.05, compared 
with non-irradiated WT controls. 
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Figure 4.4 Analyses of lung mechanics demonstrate that CCR1 deficiency, but not CCR5 
deficiency, confers protection from the decreased lung function seen after thoracic irradiation 
in WT mice. Lung mechanics were measured by FlexiVent in anesthetized, paralyzed, and 
mechanically ventilated mice at 32 weeks post thoracic irradiation. A: Static compliance (Cst) 
determined by fitting the Salazar-Knowles equation to pressure-volume curves. B: Tissue 
Elastance (H) determined by applying prime wave impedance values to the constant phase 
model. Values shown are the means±SEM of 6-9 mice per group. * p < 0.05, compared with 
non-irradiated controls of the same genotype. 
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these findings showed that CCR1-/- mice also have preserved lung function after thoracic 
irradiation. 
4. CCR1-deficient mice have less inflammatory cell infiltration into the lung after 
thoracic irradiation 
To better understand the inflammatory events following thoracic irradiation, subtypes of 
inflammatory cells were analyzed by flow cytometry. As demonstrated in Figure 4.5A, the 
CD45+ leukocytes in the irradiated WT lungs decreased within the first week after irradiation 
and gradually returned at 4 weeks post-irradiation. By 12 weeks post-irradiation, the total 
number of leukocytes was significantly higher than the basal level, remaining elevated during 
the pneumonitic phase (12-20 weeks). In contrast, the total lung leukocytes of irradiated 
CCR1-/- mice decreased at the first week post-irradiation and gradually returned to the basal 
level, but never surpassed the basal level. The changes of lung CD4+ lymphocytes and CD8+ 
lymphocytes after irradiation showed a similar pattern as total leukocytes (Figure 4.5B&C). 
Both lung CD4+ lymphocytes and CD8+ lymphocytes in the irradiated WT and CCR1-/- mice 
were significantly lower than the basal level at 1 and 4 weeks post-irradiation. In WT mice, 
both lung CD4+ T cells and CD8+ T cells increased at 12 weeks post-irradiation and remained 
elevated above the basal levels during the following period. At 12 weeks post-irradiation, 
both lung CD4+ T cells and CD8+ T cells in the irradiated CCR1-/- mice were close to the 
basal levels. CD4+ and CD8+ essentially never exceeded the basal levels except for CD4+ T 
cells at 20 weeks. The irradiated WT mice also had increased macrophages (F4/80+) 
beginning at 12 and 32 weeks post-irradiation that was not observed in the irradiated CCR1-/- 
mice (Figure 4.5D). Consistently, we saw a number of large macrophages in histologic 
sections of WT mouse lungs at 32 weeks 
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Figure 4.5 Infiltration of leukocytes into the lung post-irradiation. WT and CCR1-/- mice 
received a single dose of 14.5 Gy thoracic irradiation. Lungs and minced were harvested at 0, 
1, 4, 12, 20 and 32 weeks post-irradiation. After enzymatic digestion, the cells were stained 
with FITC, PE, PerCP, or APC labeled monoclonal antibodies to murine CD45, CD3, CD4, 
CD8, and F4/80 (Pharmingen) and then analyzed on a FACScan with Cytomation software. 
A. Increased CD45+ leukocytes in the lungs of irradiated WT mice, but not CCR1-deficient 
mice. B. Fewer CD4+ T cells and CD8+ T cells accumulated in the lungs of CCR1-deficient 
mice than WT mice after thoracic irradiation. C. Increased macrophage/monocyte in the 
lungs of irradiated WT mice but not CCR1 deficient mice. D. Arrows indicate increased 
foamy macrophages in H&E staining of irradiated mouse lungs. * p < 0.05, compared with 
non-irradiated controls of the same genotype. φ p ≤ 0.05, compared with irradiated WT at the 
same time point. 
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post-irradiation, but not in CCR1-/- mice (Figure 5E). Macrophages are considered an 
initiator of fibrosis, and thus, we saw a correlation between CCR1 expression and 
macrophage accumulation and fibrosis after irradiation. Furthermore, our data demonstrate 
that CCR1-/- mice are significantly protected lung from the cellular and histologic changes 
seen in the lungs of the irradiation in WT mice.  
5. CCR1-/- mice have decreased TGFβ1 production after thoracic irradiation 
An association between TGF-β1 production and pulmonary fibrosis has been well 
documented [34].  We therefore compared levels of this cytokine in C57BL/6J and CCR1-
deficient animals at 32 weeks after 14.5 Gy of thoracic irradiation (Figure 4.6). The TGF-β1 
levels were significantly increased in WT mice, but not in CCR1-/- mice. This increase in 
TGF-β1 levels was not seen in CCL3-deficient mice either as shown in chapter III (Figure 
3.5).   
6. TH1 and TH2 cytokine analyses after thoracic irradiation 
A key role for proinflammatory cytokines is suggested by detecting, blocking, or 
augmenting cytokine expression in various experimental models of lung fibrosis [31, 32]. In 
order to investigate the role of TH1 and TH2 cytokines in the development of radiation 
induced lung injury, we used TaqMan gene expression assays to determine the expression of 
some crucial cytokines. Although there was no significant change in IFN-γ expression in the 
irradiated WT mice, there were significant increases seen in the irradiated CCR1-/- mice at 4 
and 12 weeks (Figure 4.7A). A transient drop in IL-12p40 expression levels occurred in WT 
mice and CCR1-/- mice at 1 week post-irradiation, but IL-12p40 expression increased in WT 
mice and remained elevated through 32 weeks post-irradiation (Figure 4.7B). In contrast, IL-
12p40 expression 
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Figure 4.6 Increased TGF-β protein at 32 weeks post-irradiation in WT, but not in CCR1-/- 
mice. TGF-β protein in right lungs was measured by ELISA (Promega, Madison, WI). 
Values shown are means±SEM of 6-13 animals of each genotype. * P values < 0.05, 
compared to the nonirradiated controls of the same genotype mice. 
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Figure 4.7 TH1 and TH2 cytokine gene expression. Total RNA isolated from the left lungs at 
0, 1, 4, 12, 20, and 32 weeks post-irradiation was analyzed by quantitative real-time PCR 
using commercial TaqMan gene expression assays (Applied Biosystems). Data were 
analyzed using the 2-∆∆CT method. Data presented as the fold change in gene expression 
normalized to an internal control gene, glucuronidase beta (Gusb) and relative to a calibrator 
sample (nonirradiated mouse). A. interferon gamma (IFN-γ), B.IL-12, C. IL-4, D. IL-13 
expression. * p < 0.05, compared to nonirradiated controls of the same genotype. 
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increased only at 4 weeks post-irradiation in CCR1-/- mice and then decreased to the basal 
level.  The pro-fibrotic cytokine IL-4 started to increase at 12 weeks, peaked at 20 weeks and 
remained elevated through 32 weeks post-irradiation in WT mice (Figure 4.7C). In contrast, 
CCR1-/- mice had no increase in IL-4 expression after irradiation. Expression of another 
important pro-fibrotic cytokine, IL-13, increased in the irradiated WT mice at 20 and 32 
weeks (4-fold increase). In contrast, there was no increase of IL-13 expression in the 
irradiated CCR1-/- mice (Figure 4.7D). In summary, the irradiated WT mice had increased 
expressions of the profibrotic TH2 cytokines IL-4, and IL-13 which were not seen in the 
irradiated CCR1-/- mice, while the irradiated CCR1-/- mice have slightly increased expression 
of antifibrotic TH2 cytokines IFN-γ. 
7. CCR1 inhibitor (BX471) attenuates radiation-induced lung injury 
Our data showed that the genetic deficiency of CCR1 is radioprotective, suggesting that 
targeting this receptor with an antagonist might be therapeutically useful. Therefore, we 
tested whether blocking CCR1 signaling with a specific inhibitor (BX471) could protect WT 
mice from radiation-induced lung injury. BX471 is one of the most extensively studied 
CCR1 small molecular inhibitors. BX471 has previously been shown to ameliorate renal 
inflammation and fibrosis, chronic fungal asthma, and pancreatitis-associated lung injury in 
rodent models [93, 177, 178]. Thus, we tested BX471 in our model for its efficacy as a 
radioprotector. 
Irradiated WT mice treated with twice daily injection of 30 mg/Kg BX471 from 3 weeks 
to 7 weeks post-irradiation had complete protection from radiation-induced lung fibrosis as 
shown by hydroxyproline assays and confirmed by histologic analyses of whole lung samples 
(Figure 4.8A&B). Furthermore, we show that when compared with mice receiving vehicle  
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Figure 4.8 The CCR1 inhibitor BX471 reduces radiation-induced lung fibrosis. A. 
Quantitation of collagen in right lungs as determined by measurements of hydroxyproline at 
32 weeks post-irradiation. nonIR=non-irradiated and non-treated; IR+vehicle=irradiated and 
treated with daily subcutaneous injection of vehicle (40% Cyclodextrin) from week 3 to 
week 7 post-irradiation; IR+BX471=irradiated and treated with daily subcutaneous injection 
of BX-471 at 30 mg/Kg of body weight from week 3 to week 7 post-irradiation. Values 
shown are the means±SEM. N= number of mice per group. There was no increase in the 
collagen content in the lungs of irradiated mice receiving BX471 as was seen in the vehicle-
treated irradiated mice. B. Lungs of irradiated mice treated with BX471, but not vehicle-
treated, are protected from inflammation and fibrosis. 
IR + Vehicle 
IR + BX471 
B 
n=12
n=16
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P<0.001 P<0.001A
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only, irradiated WT mice receiving BX471 treatment had preserved lung function after 
thoracic irradiation (Figure 4.9). Not surprisingly, irradiated WT mice that received vehicle 
treatment had significantly diminished lung function as shown by a reduced lung compliance 
and increased lung tissue elastance. In contrast, irradiated WT mice receiving twice daily 30 
mg/Kg BX-471 treatments had significantly higher compliance and lower tissue elastance 
than vehicle treated irradiated mice. Thus, BX471 did successfully reproduce the 
radioprotected phenotype we saw with mice having a genetic deficiency of CCR1. 
 
IV.E. Discussion 
We used mice with targeted mutants to study the roles of the CCL3 receptors, CCR1 and 
CCR5, in mediating radiation-induced lung injury. Our studies show that either the genetic 
deficiency or the blockade of CCR1 effectively reduces the inflammatory cell infiltration and 
subsequent lung fibrosis seen after thoracic irradiation. In contrast, lack of CCR5 exacerbates 
radiation lung injury. 
1. Lack of CCR1 protects from radiation-induced lung injury 
Chemokines are fundamental regulators of leukocyte homeostasis and inflammation, and 
their antagonism by small molecule chemokine receptor antagonists may be therapeutic 
important in human respiratory diseases. The CC and CCR chemokine families have 
important regulatory roles in fibrotic processes. In particular, CCL3 and CCL2 (monocyte 
chemoattractant protein 1, MCP-1), that are chemotactic for mononuclear, phagocytes, have 
been identified as essential pro-fibrotic mediators [140]. Blocking the function of CCL2 or 
CCL5 significantly decreased proteinuria as well as numbers of infiltrating leukocytes during 
crescentic nephritis [179]. CCR2-deficient mice produced similar results, confirming crucial  
 94 
 
0.05
0.06
0.07
0.08
0.09
0.10
Control Vehicle BX471
C
st
  (
m
L/
cm
H
2O
)
A 
φ
*
 
0
5
10
15
20
25
30
35
Control Vehicle BX471
H
 (c
m
H
2O
.s
/m
L)
B 
 
Figure 4.9 BX471 treated WT mice had preserved lung function after thoracic irradiation. 
Lung mechanics were measured by FlexiVent in anesthetized, paralyzed, and mechanically 
ventilated mice at 32 weeks post thoracic irradiation. A: Static compliance (Cst) determined 
by fitting the Salazar-Knowles equation to pressure-volume curves. B: Tissue Elastance (H) 
determined by applying prime wave impedance values to the constant phase model. Values 
are means±SE of 6-9 mice per group. Control=non irradiated, Vehicle=irradiated mice 
treated with vehicle from week 4 to 7 after irradiation, BX471=irradiated mice treated with 
BX471 from week 4 to 7 after irradiation *p<0.05 compared with non-irradiated control; φ 
p<0.05, compared with irradiated WT treated with vehicle.  
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roles for the CCL3- and CCL2-mediated signaling pathways in renal fibrogenesis [76, 144]. 
The mRNA expression of BLC, C10, IP-10, CCL2, CCL7 , CCL9, CCL5, CCR1, CCR2, 
CCR5 and CCR6 was elevated in fibrosis-sensitive (C57BL/6) mice at 26 weeks post-
irradiation at the dose of 12.5 Gy thoracic radiation [16]. We also found that CCL3 is a 
mediator of radiation-induced lung injury and the lack of CCL3 attenuates lung fibrosis in 
our model.  
The major receptor for CCL3, CCR1 is an important recruiter for leukocyte to sites of 
inflammation. CCR1 has been implicated as an attractive therapeutic target for modulating 
leukocyte-mediated tissue damage. For example, anti-CCR1 antibodies significantly reduced 
the accumulation of inflammatory cells and collagen deposition, with dramatic improvement 
in survival after bleomycin lung injury [146]. CCR1 mediates leukocyte recruitment and 
subsequent renal fibrosis after unilateral ureteral obstruction, the CCR1 inhibitor BX471 
significantly reduced leukocyte recruitment, especially macrophages, and, thus diminished 
renal fibrosis [180]. 
Our studies show that in WT mice CCR1 gene expression began to significantly increase 
by 4 weeks following irradiation and remained elevated through 32 weeks. Coincident with 
this increase in CCR1 expression, numerous leukocytes were recruited into the lung. 
Ultimately, collagen deposition and lung fibrosis ensued. In contrast, both CCR1-/- and 
BX471-treated mice were protected from these changes with resultant improved survival and 
preserved lung function. Thus, our data indicate that deficiency of CCR1 precludes both 
pneumonitis and subsequent fibrosis, suggesting a crucial linkage of these processes. 
Furthermore, only short term treatment (4 weeks was as effective as 8 weeks) with a specific 
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CCR1 inhibitor during the early pneumonitic phase can prevent the entire spectrum of long-
term sequalae, including fibrosis, loss of lung function and premature death. 
2. Lack of CCR5 exacerbates radiation-induced lung injury 
CCL3 binds and signals through both CCR1 and CCR5. Both receptors are co-expressed 
on macrophages and T cells.  In contrast to CCR1, whose absence or blockade resulted in 
significant protection from radiation lung injury, the lack of CCR5 exacerbated lung fibrosis 
and function damage. CCR5-deficient mice have marked reduction in T cell recruitment into 
the lung from Aspergillus fungigatus conidia-induced asthma and into the brain after 
Cryptococcus neoformans infection [181, 182]; however, in the absence of CCR5, greater 
number of primed T lymphocytes were recruited into the lung in Mycobacterium tuberculosis 
infected mice [183]. CCR5-deficient mice had increased infiltration by CD4+ and NK1.1+ 
lymphocytes in a murine model of colitis using dextran sodium sulfate [184]. We also 
observed increased leukocyte recruitment in the lungs of irradiated CCR5-/- mice in our 
model (data not shown). CCR5 mediates lymphocyte trafficking, whereas macrophage 
recruitment is CCR5-independent [185].  Histologically many macrophages were seen in the 
lungs of irradiated CCR5-deficient mice; however, we have not yet quantified the subsets of 
recruited inflammatory cells. 
CCR5 is highly expressed on TH1 cells and may be critical for the promotion of TH1-type 
immune responses in mice. CCR5-deficient mice had a decrease in TH1, and an increase in 
TH2, cytokine expression in a murine colitis model [184]. We also observed increased 
expression of the TH2 cytokine, IL-4, in irradiated CCR5-deficient mice (data not shown), 
suggesting a role of TH2 cells in their worsened phenotype. CCR5 also regulates the homing 
of T regulatory cells (T-reg) and CCR5 deficiency prevented T-reg cells from reaching the 
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site of Leishmania major infection, thereby altering the course of the disease [186]. Together, 
these findings suggest that, in comparison with WT mice, CCR5-/- mice may have fewer T-
reg cells, and increased TH2 immune response in the lung after thoracic irradiation with the 
resultant exacerbated lung injury. 
One of CCR5 ligands is CCL3. The fact that CCR5-/- mice have worse radiation lung 
fibrosis compared to WT mice, may explain that CCL3 deficiency attenuates radiation lung 
fibrosis but CCR1 deficiency abolishes radiation lung fibrosis.  
3. Clear differences in the levels and timing of cytokine gene expression in the lungs 
of irradiated WT and CCR1-/- mice 
TGF-β is a central cytokine in fibrotic processes as it induces lung fibroblast transcription 
and synthesis of collagen and various other components of the extracellular matrix, e.g., 
fibronectin, glycosaminoglycans, and proteoglycans [35]. Patients with higher plasma TGF-ß 
levels before, or during, thoracic radiation, have a higher risk of developing pneumonitis [37, 
38]. In rat model of thoracic irradiation TGF-β in BAL fluid was up-regulated and peaks 
between 3 and 6 weeks, coincident with the initial influx of inflammatory cells in BAL fluid, 
but preceding histologically discernable pulmonary fibrosis, suggesting a pathogenetic role 
of TGF-β in the development of radiation fibrosis [39]. Consistently, our studies showed 
increased TGF-β1 levels in the lungs of irradiated WT mice that developed lung fibrosis. In 
contrast, increased TGF-β1 levels were not seen in irradiated CCR1-/- and CCL3-/-mice that 
did not have fibrosis. Our interpretation is that macrophages are the major source of TGF-β1 
as CCR1-/- mice have minimal macrophage infiltration compared to WT mice after thoracic 
irradiation; however, we have not yet specifically examined the role of recruited fibrocytes in 
our model. 
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CD4+ T cells are classified as TH1 and TH2 cells according to their cytokine production 
[49, 50]. The main TH1 cytokines are IFN-γ and IL-12, whereas TH2 cytokines include 
interleukin-4 (IL-4), IL-5 and IL-13. TH2 cytokines are generally activators of fibroblasts and 
may promote extracellular matrix deposition and remodeling [52]. TH1 cytokines, 
particularly IFN-γ,  appear to have antifibrotic effects by inhibiting myofibroblasts [54, 55]. 
A shift from a TH1 to a TH2 cytokine profile is likely to be a key event in the progression of 
inflammation to fibrosis in IPF [53]. Although increased lung IL-4 expression was found in 
hemi-thoracicaly radiated rats [62], it was still unknown whether radiation-induced lung 
fibrosis may be TH1 or TH2-mediated. Our present study showed that the radiation-induced 
lung injury increases cytokine expression and thus enhances lung inflammation. The 
irradiated WT mice had significantly increased IL-12 expression by 4 weeks post-irradiation 
after an initial transient drop, whereas there was no significant change in IFN-γ expression. 
In contrast, expression of the TH2 cytokine IL-4 started to increase at 12 weeks post-
irradiation, peaking at 20 weeks, and IL-13 expression, one of main pro-fibrotic mediators, 
increased at 20 weeks and continued increasing to 32 weeks. Consistent with these increases 
in profibrotic cytokines, histologic evidence of lung fibrosis starts around 20 weeks after 
thoracic irradiation. In contrast, neither IL-4 nor IL-13 expression increased in the 
radioprotected CCR1-/- mice after thoracic irradiation. Furthermore, irradiated CCR1-/- mice 
showed increased IFN-γ  expression at 4 weeks and 12 weeks. Together, these data implicate 
TH2 cells in mediating fibrosis. Interestingly, the lack of CCR1 has been shown to enhance 
TH1 response in nephrotoxic nephritis in the mouse, including titers of antigen-specific IgG2a 
antibody, delayed-type hypersensitivity responses, and production of IFN-γ and TNF-α [187].  
On the other hand, CCR5-/- mice have even worse radiation-induced fibrosis than WT, which 
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supports that TH2 mediation of radiation-induced fibrosis as CCR5 is preferentially expressed 
in TH1 cells. In summary, our findings suggest that a shift towards a TH2 cytokine pattern 
occurs around 12 to 20 weeks after thoracic irradiation that may directly affect the overall 
pattern of proliferation and/or extracellular matrix gene expression of lung fibroblasts, 
resulting in development of fibrosis. Further study is needed to more completely address this 
issue, such as using TH1 or TH2 knock-out animals or possibly adoptive transfer of these TH 
subsets into protected mice.  
4. The CCR1 inhibitor, BX471 effectively reduces radiation-induced lung 
inflammation and fibrosis 
A number of pharmaceutical companies have identified small molecule CCR1 
antagonists [177]. Among them, BX471 is one of most extensively studied CCR1 small 
molecular inhibitors. BX471 has been shown to ameliorate renal inflammation and fibrosis 
[180], chronic fungal asthma [78], and pancreatitis-associated lung injury in rodent models 
[79]. BX471 reduced leukocyte recruitment in unilateral ureteral obstruction model [188].  In 
our murine model of radiation-induced lung injury, 4 week-treatment with BX471 
significantly eliminates lung injury and preserved lung function. This finding was consistent 
with the beneficial effects we saw with genetically-induced CCR1 deficiency. Our studies 
clearly suggested a key role for CCR1 is to recruit macrophages and T cells into the lung 
after thoracic irradiation. Currently, BX471 has been tested in clinical phase I and II trial in 
patients with psoriasis and in phase II trial in patients with multiple sclerosis. Although these 
clinical trials did not show significant benefit, we hypothesize that using BX471 for 
preventing radiation lung injury may be a more feasible target than using BX471 for 
dampening well-established autoimmune diseases. 
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In summary, CCR1 plays an important role in mediating the infiltration of inflammatory 
cells into the lung after thoracic irradiation. Lack of CCR1 reduced lymphocyte and 
monocyte/macrophage infiltration, the expression of profibrotic cytokines, IL-4, IL-13 and 
TGF-β, and the subsequent lung fibrosis after thoracic radiation. Moreover, the blockade 
with the CCR1 antagonist BX471 reproduced these protective effects in radiation-induced 
lung injury. Cumulatively, these observations demonstrate that CCR1 blockade may offer a 
new therapeutic strategy to ameliorate radiation-induced pneumonitis and fibrosis.  
 
 
IV.E. The Effects of BX471 on tumor cells (ongoing study)  
 Chemokines and their receptors in cancer have well-established roles in cancer. 
Chemokines are involved in almost all aspects of tumor establishment and progression: they 
provide directional cues for migration/metastasis, shape the tumor microenvironment and 
provide survival and/or growth signals [105, 106, 189]. In chronic inflammation, leukocyte 
recruitment, led by chemokines and chemokine receptors, may contribute to tumor growth 
and spread by inducing the expression of growth or survival factors and matrix 
metalloproteases. Additionally, chemokines are involved in tumor angiogenesis and in the 
homing of tumor cells to the sentinel lymph nodes and subsequent metastasis.  
Notably, CC-chemokines have implicated in regulating the progression of many 
tumors such as breast cancer, melanoma, lung cancer, colorectal carcinoma, multiple 
myeloma, prostate cancer and ovarian cancer [106]. The chemokine ligand-receptor pair, 
CCL3/CCR1 facilitates tumor growth and metastasis in oral squamous cell carcinoma[190], 
hepatocellular carcinoma cell[191], solid ovarian tumors [192], myeloma and breast cancer. 
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Increased CCL3 expression is believed to play an important role in the development of lytic 
bone lesions in multiple myeloma and treatment with a monoclonal rat anti-mouse CCL3 
antibody reduced both paraprotein levels and lytic lesions in mice inoculated with myeloma 
cells [193]. Thus, an additional benefit of CCR1 inhibition may include some antitumor 
effects. For example, the  CCR1&5 antagonist, Met-CCL5 inhibits experimental breast tumor 
growth [194]. Similarly, the CCR1 antagonist BX471 reduces osteolytic lesions by 40% in 
myeloma 5T2MM mice [195].  
We have shown that BX-471 effectively protects mice from radiation-induced lung 
injury.  Clinically, many cancer patients who receive thoracic radiotherapy suffer from 
radiation-induced lung injury. In order to potentially use BX-471 for these patients, we 
should first understand the effects of BX-471 on tumors. Therefore, we plan to evaluate 
whether BX-471 affects tumor radiosenstivity and/or enhances tumor growth/metastasis. As 
Lewis lung carcinoma cells (LLC) are immunologically compatible with C57BL/6 mice, we 
have chosen this tumor cell line for these studies. 
For tumor radiosenstivity experiments, Lewis lung carcinoma cells will be 
subcutaneously injected into mouse chest walls. When the transplanted tumors become 
palpable (about 6mm), one group of mice will receive thoracic radiation at a single dose of 
14.5 Gy, a second group will receive 30 mg/kg BX-471 twice daily for 2-4 weeks, and the 
third group will receive both treatments. Mice will be observed daily and euthanized for 
analyses when tumor sizes reach 2 cm or by 4 weeks post-irradiation. 
To evaluate the effects of BX-471 on tumor metastasis, one cohort of mice will be 
treated with 30 mg/kg BX-471 twice daily for 1 week and the other cohort are treated with 
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vehicle (40% cyclodextrin/saline). After 1 week, Lewis lung carcinoma cells will be injected 
into tail veins while treatment with BX471 or vehicle continues. After 3 weeks post LLC cell 
transfer, mice will be euthanized and lungs harvested for the number and average size of 
tumor metastases. 
These studies will add to our current data as a basis for clinical trials of BX-471 in 
cancer patients undergoing thoracic radiotherapy. 
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V. The TH1/TH2/TH17 paradigm and Radiation-induced Lung injury 
V.A. Introduction 
Radiation pneumopathy is an important dose-limiting complication of radiotherapy 
for which the pathogenesis is only partially understood, though initially, inflammation and 
pneumonitis predominate. One feature of radiation induced pulmonary injury is infiltration of 
inflammatory cells. As shown in our studies, and others, a variety of inflammatory cells are 
recruited into the lung after irradiation [15, 196]; however, specific functions for 
inflammatory cell subtypes remain poorly defined.  
Radiation lung fibrosis is thought to develop through a number of nonexclusive 
mechanisms. One described mechanism is that damage to specific cells (i.e., epithelium or 
interstitial fibroblasts) stimulates them to alter their expression of inflammatory and 
chemotactic cytokines, which in turn act to recruit and activate inflammatory cells. Once 
recruited into the disturbed microenvironment, the stimulated inflammatory cells produce 
other mediators, thereby initiating a complex ‘‘cytokine cascade’’, and ultimately, leading to 
an overt, functionally significant, pneumonitis. In addition, during this persistent chronic 
inflammation, the activated cells, both inflammatory and parenchymal, can produce 
mediators that directly affect the overall pattern of proliferation and/or matrix gene 
expression of lung parenchymal fibroblasts, leading to fibrosis.  
Several experimental models have shown the importance of CD4+ T cells in the 
progression of fibrosis, including radiation lung injury [34]. Depletion of CD4+, but not 
CD8+, T cells reduced the production of TGF-β and lung fibrosis in bleomycin-treated T-bet-
deficient mice [197] and reduced the postirradiation parenchymal thickening in irradiated rat 
lungs [62]. Our studies show clear differences in the lung inflammatory cell content, 
including CD4+ T cells, CD8+ T cells and macrophages, after thoracic irradiation in 
radiosensitive animals (WT) and radioprotected animals (CCL3-/-, CCR1-/-).  
Naive CD4+ T helper cells can differentiate into one of three lineages of effector T 
helper cells, i.e., TH1, TH2 or TH17 cells. TH1 cells produce mainly pro-inflammatory 
cytokines IL-1, IL-2, IL-12, IL-15, IL-18, IFN-γ and lymphotoxin (TNF-β), while TH2 cells 
are the source of IL-4, IL-5, IL-6, and IL-13. TH1 cytokines IL-2, IFN-γ, and TNF-β activate 
cytotoxic T cells (Tc) and macrophages to stimulate cellular immunity and inflammation. 
The TH2 cytokines IL-4, IL-5, IL-6, and IL-10 stimulate antibody production by B cells and 
mediate anti-parasite immunity and allergic diseases. TH17 cells express IL-17, IL-17F, IL-
21 and IL-22 (and IL-26 in humans) and act to regulate inflammatory responses [51]. The 
presence of IL-12 [signaling through signal transduction and activator of transcription 
(STAT)-4] skews towards TH1, IL-4 (signaling through STAT-6) towards TH2, and IL-6 and 
TGF-β towards TH17 differentiation (signaling through STAT-3) [49, 50]. In addition, TH1 
and TH2 type cytokines, notably IL-2, IFN-γ, and IL-4, inhibit TH17 differentiation. 
In general, fibrogenesis is more strongly associated with the TH2 CD4+ T cell 
response involving IL-4, IL-5, and IL-13 [34]. TH2 cytokines have direct profibrotic effects, 
and also promote the expression and activation of the fibrogenic cytokine TGF-β1. For 
example, a predominant TH2 cytokine (IL-4 and IL-5) profile is revealed in idiopathic 
pulmonary fibrosis (IPF) by immunostaining and in situ hybridization of open lung biopsy 
specimen. A shift from the TH1 to TH2 cytokine profile is a likely key event in the 
progression of inflammation to fibrosis in IPF [47, 53]. Alternatively, TH1 cytokines, in 
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particular IFN-γ, have antifibrotic effects by inhibiting myofibroblasts [54, 55]. Although 
changes in both TH1 cytokines and TH2 cytokines have been observed in several studies of 
radiation lung injury, our results suggest that radiation lung fibrosis is more likely mediated 
by TH2 cytokines (see chapter IV). However, same further study is needed to confirm these 
findings. 
IL-17 is produced primarily but not exclusively, by CD4+ and CD8+ αβ T cells; 
however, γδ T cells can also produce IL-17. In the lung, NKT cells may be another source of 
IL-17. Thus, IL-17 production may be regulated by different cells and different cytokines in 
different organs [51]. TH17 cells have distinct biological functions from other TH cells. TH17 
cells are reportedly key players in several autoimmune and inflammatory diseases, i.e. 
rheumatoid arthritis, asthma, systemic lupus erythematosus, colitis and allograft rejection 
[198]. Overexpression of IL-17 in the lungs induces the production of various cytokines, 
chemokines and adhesion molecules, resulting in increased leukocyte infiltration [199, 200]. 
Together, IL-17 and TNF promote pro-inflammatory TH1 cytokine gene expression. On the 
other hand, IL-17F-deficient mice have enhanced TH2 cytokine production, while IL-17-
deficient mice show a reduced TH2 response [201].  
TH17 cells are enriched in the lung and GI tract, and are considered important in 
mucosal host defenses and other pulmonary diseases. A particular IL-17F mutation that 
antagonizes the activity of wild-type IL-17F was associated with airway inflammatory 
diseases, like human asthma and chronic obstructive pulmonary disease [202]. Both IL-17 
and IL-17F are induced in a dose- and time-dependent fashion in K. pneumoniae infection 
and was associated with neutrophil emigration into the lung [203]. IL-23, and the 
downstream cytokines IL-17A and IL-17F, may be involved in the proinflammatory cytokine 
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network involved with the pathogenesis of cystic fibrosis [204]. IL-17 might also play an 
indirect role in airway remodeling in asthma by regulating local airway inflammation and 
profibrotic cytokine production [205]. In a rat model of bleomycin-induced lung injury, γδ T 
cells were the predominant source of IL-17. In this model, γδ T cell knockout mice showed 
more severe interstitial inflammation, but a significantly reduced cellular infiltration into the 
airways, reduced IL-6 and IL-17 expression in the lung, and a significant delay in epithelial 
repair (collagen deposition) [206]. Increased IL-17 production was observed in tissue fibrosis 
after chronic 2,4,6-trinitrobenzene sulfonic acid-induced colitis [207]. Lastly, IL-17 may also 
contribute to stromal fibrosis in nasal polyp disease [208]. The potential dynamics of TH17 
cell population and their interaction with other T helper cells have not yet been studied in 
radiation fibrosis.  
A further subset of T cells, termed T regulatory (T-reg) cells, have immunosuppressive 
functions and a cytokine profile distinct from that of either TH1 or TH2 cells. TReg cells are 
able to inhibit the development of TH2 cell responses, as well as TH1 cell responses, by 
producing high levels of IL-10 and TGF-β. TReg cells also modulate or suppress 
inflammatory responses from TH17 cells, which are often present at the interface between the 
external and internal environments and mediate a number of autoimmune diseases. Although 
TGF-β induces Foxp3 in naive T cells, thereby generating Treg cells, TGF-β and IL-6 
together drive the generation of TH17 cells. Thus, the induction of TH17 cells is 
dichotomously related to the induction of Foxp3+ Treg cells: IL-6 is one of the switch factors 
that re-direct T cell differentiation from T-reg pathway into the TH17 pathway. Treg cells 
were implicated in bleomycin-induced lung fibrosis [41]; however, studies of Treg cell 
functions in radiation-induced lung injury are thus far lacking. 
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We hypothesize that in response to radiation, the early proinflammatory cytokine 
expression, regulated by different populations of CD4+ T helper cells, may directly or 
indirectly promote the development of radiation lung fibrosis. The aim of this study was to 
define the functions of CD4+ T lymphocyte subsets in the pathogenesis of post-irradiation 
pneumonitis and fibrosis. 
V.B. Materials and Methods 
1. Mice  
All animal studies were performed under approval by the IACUC at the University of 
North Carolina at Chapel Hill. Wild-type, CD4-/- and CD8-/- C57BL6mice were purchased 
from Jackson Laboratories. IL-10/IL-12 double knockout C57BL6 mice (IL-10/12-/-) [68] 
were obtained from Taconic Farms (Germantown, NY). IL-17 receptor A knockout mice (IL-
17RA-/-) were obtained from Dr. Jay Kolls in NIEHS. All strains of mice were bred 
according to DLAM policies and housed in microisolator cages maintained in a specific 
pathogen-free environment. All mice except those used in lung cytokine protein assays were 
male. 
2. Thoracic irradiation 
Animals were irradiated with a singled dose of 14.5 Gy as described in chapter II.  
3. Hydroxyproline (HYP) assay 
Hydroxyproline assay were performed as described in chapter II. 
4. Cytokine protein analyses 
Irradiated female mouse lungs were homogenized in 1 ml of a protease inhibitor cocktail 
(φ complete protease inhibitors cocktail, Roche), then incubated on ice for 30 min and 
centrifuged at 1,4000rpm for 15 min at 4°C. Supernatants were aliquoted and stored at –70 
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°C before performing cytokine protein assays on the Luminex 100 by using a Bio-plex 
mouse cytokine 23-Plex Panel (catalog # 171-F11241, BIO-RAD, Hercules, CA) according 
to manufacturer’s manual. Bio-plex cytokine assay kits simultaneously measure IL-1α, IL-
1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, Eotaxin, 
G-CSF, GM-CSF, IFN-γ, KC, MCP-1, MIP-1α, MIP-1β, RANTES, and TNF-α. 
5. Gene expression analyses 
Gene expression analyses were performed as described in chapter II. 
6. Histologic analyses 
Histologic analyses were performed as described in chapter II.  
7. Measurements of lung mechanics 
Measurements of lung mechanics were performed as described in Chapter II. 
8. Antibodies and flow cytometry 
Antibodies with the following specificities were purchased from eBiosciences (San Diego, 
CA): anti-CD4 (RM 4.5), CD8 (53-6-7), IFN-γ (XMG1.2), IL-17F (eBio 18F10), F480 and 
Foxp3. Antibodies to IL-17A (TC11-18H10.1) and TNF-α (MP6-XT22) were purchased 
from Biolegend (San Diego, CA). Acquisition was performed on a FACSCalibur using 
CellQuest software (BD Biosciences; San Jose, CA). Analyses were performed using FlowJo 
software (Treestar Inc., Ashland, OR). Mice were euthanized at several time points post-
irradiation and lung leukocyte isolation was performed as previously described. Isolated cells 
were stimulated with PMA, ionomycin, and brefeldin A. Intracellular cytokine staining was 
performed using the Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s 
recommendations. 
9. In vitro suppression assays 
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Treg-mediated suppression was measured by a previously described protocol [209]. 
Briefly, allogeneic stimulators were prepared from spleen cell suspensions of B6D2 mice, 
depleted of T cells using anti-CD90 magnetic beads (Miltenyi Biotech), and irradiated with 
2100 cGy from a 137Cs source. Stimulators (1 × 105) were incubated with responders (WT 
CD4+CD25- T cells, 1 × 105) and various ratios of Tregs from WT or CCR5-/- donors. 
Cultures were incubated for 5 days at 37°C and 1 µCi (0.037 MBq) 3H-thymidine was added 
for the last 16 hours of culture. Incorporation of 3H-thymidine was assessed. 
V.C. Results 
1. CD4-deficient mice show partially radioprotective phenotype 
Our previous studies show that the radiation injury-sensitive WT mice have greater lung 
infiltration of CD4+ and CD8+ T cells than the radioprotected CCR1-/- and CCL3-/- mice. To 
determine whether CD4+ or CD8+ T cells contribute to the pathogenesis of radiation-induced 
lung injury, CD4-/-and CD8-/-mice received thoracic irradiation. We showed that, overall, 
CD4-deficient mice had better survival at 32 weeks than WT after thoracic irradiation (76% 
vs 52%, p=0.054) (Figure 5.1A), while the survival rate for CD8-/- mice was close to that of 
WT mice. We quantified collagen deposition in lung by hydroxyproline (HYP) assays. All of 
the irradiated WT, CD4-/- and CD8-/-mice had increased lung HYP content compared with 
non-irradiated controls of the same genotype (Figure 5.1B); however, lung HYP in irradiated 
CD4-/- mice was significantly lower than that seen in irradiated WT mice. In contrast, CD8-/- 
mice had much higher lung HYP than irradiated WT mice. Consistent with lung HYP results, 
histologic analyses demonstrated that CD4-/- mice had less radiation-induced lung fibrosis 
than WT, while CD8-/- mice were worse (Figure 5.2). Lung function analyses showed that 
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both irradiated WT and CD8-/- mice had a decreased compliance and an increased tissue 
elastance, while CD4-/- mice had preserved lung functions (Figure 5.3).   
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Figure 5.1 CD4- deficient, but not CD8-deficient, mice have a partially protected phenotype 
from radiation-induced lung injury. A. Survival curves at 32 weeks post-irradiation by 
Sigmaplot 8.0 showed that CD4-/- but not CD8-/- mice have improved survival compared to 
 111
WT. WT, CD4-deficient, and CD8-deficient animals received a single dose (14.5Gy) of 
thoracic irradiation. p=0.054, CD4-/- vs WT. B. Hydroxyproline content of the right lungs of 
non-irradiated control and irradiated mice 32 weeks post-irradiation. Values shown are the 
means±SEM of 6-9 mice per group. * p < 0.05, compared with non-irradiated controls of the 
same genotype; φ p<0.01, compared with irradiated WT.  
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Figure 5.2 Histologic analyses show that CD4-, but not CD8-deficient, mice have a partially 
protective phenotype from radiation-induced lung inflammation and fibrosis. WT, CD4-/- and 
CD8-/- mice received a single dose (14.5Gy) of thoracic irradiation. Lungs were harvested at 
32 weeks post-irradiation and stained with Masson's trichrome (MT). Whole sections of MT 
stained lungs demonstrate less inflammatory and fibrotic foci in irradiated CD4-/- mice. 
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Figure 5.3 Analyses of lung mechanics demonstrate that irradiated WT and CD8-/- mice have 
decreased lung compliance and increased tissue resistance, but irradiated CD4-/- mice have 
preserved lung function. Lung mechanics were measured in anesthetized, paralyzed, and 
mechanically ventilated mice 32 weeks post thoracic irradiation. A. Static compliance (Cst) 
was determined by fitting the Salazar-Knowles equation to pressure-volume curves. B. 
Tissue Elastance (H) was determined by applying prime wave impedance values to the 
constant phase model. Values shown are the means±SEM of 6-9 mice per group. * p < 0.05, 
compared with corresponding genotype non-irradiated control. 
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2. Cytokine protein assays of irradiated WT mouse lungs 
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In order to understand what molecular mediators contribu
 fibrosis, we analyzed the lungs from irradiated female mice using Bio-Rad Plex cytokine 
protein assays. We examined these samples for their expression of IFN-γ, IL-12, IL-1β, TNF-
α as representative the TH1cytokines, and IL-4, IL-5, IL-6, IL-13 as representative the TH2 
cytokines. As shown in Figure 5.4B, the TH1 cytokine IFN-γ did not significantly change 
after this radiation treatment. Both IL-1β and TNF-α increased within 1 week but then 
returned to the basal levels (Figure 5.4C&D). Although the expression of IL-12, which is 
required for TH1 cell differentiation, increased at 20-28 weeks post-irradiation (Figure 5.4A), 
none of the TH1 cytokines (IFN-γ, IL-1β and TNF-α) increased at this later phase. In contrast, 
the profibrotic TH2 cytokines, IL-4 significantly increased at 12, 16, 24 and 28 weeks 
(Figure 5.4E) and IL-13 level increased at 28 weeks (Figure 5.4G). Lastly, the TH2 cytokine 
IL-6, which is required for TH17 differentiation, also significantly increased at 4, 8 and 24 
weeks (Figure 5.4H). We also found that protein levels of IL-17 were elevated at 4 weeks 
and 16-28 weeks post-irradiation (Figure 5.4I).. Taken together, these data support our 
hypothesis for a crucial role of TH2 cytokines in radiation pneumopathy. 
3. IL-10/12-/- mice develop severe lung fibrosis after thoracic irradi
As shown in chapter V, compared to the radioprotected CCR1-deficient m
 mice had higher mRNA expressions of the TH2 cytokines, IL-4 and IL-13. We also 
demonstrated elevated protein levels of IL-4 and IL-13 in irradiated WT female mice. Both 
 114
IL-4 and IL-13 has been shown to be profibrotic. These findings suggest that radiation- 
induced lung fibrosis may be mediated by TH2 cytokines. To validate this hypothesis, IL-
10/12-double knockout mice were thoracically irradiated. The IL-10/12-/- mice did show 
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Figure 5.4 continue 
 
 
igure 5.4 Cytokine analyses of irradiated female WT mouse lung homogenates. IL-12 (A), 
F), IL-13 (G), IL-6 (H), IL-17 (I). Values 
* p < 0.05, compared with nonirradiated 
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eficient m  worse radiation pneumopathy. 
WT and IL-10/12-double-deficient mice rece  irrad tion at dose of 14.5 Gy. (A) 
Survival curves at 25 weeks post-irradiation by Sigmaplot 8.0 showed IL-10/12-double-
deficient mice have much worse survival. (B) Hydroxyproline assays show that the irradiated 
IL-10/12-/- mice have both much worse and earlier onset of pulmonary fibrosis. (C) Gene 
expression of collagen 3α1 increased after thoracic irradiation. * p < 0.05, compared with 
non-irradiated controls of the same genotype. 
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enhanced TH2 responses (increased IL-4 and IL-13 expression) and severe lung fibrosis.  
In our model of radiation-induced lung injury, irradiated IL-10/12-/- mice have markedly 
increased premature death at 25 weeks post-irradiation compared to irradiated WT (26% vs 
79%, p=0.02) (Figure 5.5A). Moreover, the irradiated IL-10/12-/- mice have much worse and 
earlier onset of pulmonary fibrosis (Figure 5.5B). By 20 weeks post-irradiation the irradiated 
ing period in both irradiated WT and IL-
0/12-/- mice (Figure 5.5C). As expected, histologic images show that irradiated IL-10/12-/- 
ice had diffuse inflammation and fibrosis compared to only focal inflammation and fibrosis 
in WT mice (Figure 5.6). Consistent with our hydroxyproline and histologic analyses, lung 
function analyses showed decreased lung compliance and increased tissue elastance in the 
irradiated IL-10/12-/- mice at 20 weeks post-irradiation (Figure 5.7).Changes in lung 
compliance and tissue elastance were similar to what we saw in irradiated WT mice at 32 
weeks post-irradiation. While irradiated WT mice at 20 weeks post-irradiation already had 
some decreased lung compliance and increased tissue elastance compared to WT control 
mice, their lung function was better than IL-10/12-/- mice at the same time point.  
In summary, in our model of radiation-induced lung injury, IL-10/12-/- mice have much 
worse and earlier onset of fibrosis, and greater mortality after thoracic radiation, again 
supporting TH2 cells as mediators of radiation lung injury. 
 
IL-10/12-/- mice already had significantly greater lung hydroxyproline content not only 
compared to non-irradiated control IL-10/12-/- mice, but also compared to the irradiated WT 
mice at 32 weeks post-irradiation. Collagen 3α1 gene expression increased at 1 week post-
irradiation and remained elevated in the follow
1
m
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 Figure 5.6 Histologic analyses show that the IL-10/12-/- mice have even worse radiation-
induced lung injury than irradiated WT mice. WT and IL-10/12-/- mice were thoracically 
irradiated with a single dose of 14.5 Gy. The lungs from WT and IL-10/12-/- mice were 
harvested at 32 and 20 weeks post-irradiation, respectively, and stained with Masson's 
trichrome (MT). Whole sections of MT-stained lungs show worse inflammatory and fibrotic 
foci in IL-10/12-/- mice. 
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equation to pressure-volume curves. B: Tissue Elastance (H) was determined by applying 
prime wave impedance values to the constant phase model. *p<0.05 compared with 
corresponding age-matched controls. 
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Inf4. lammatory cells infiltrates differ  in IL-10/12-/- and WT mice after irradiation 
Flow cytometric analyses showed that the IL-10/12-/- mice had increased CD4+ T cells at 
20 weeks post-irradiation (Figure 5.8A), while CD4+ T cells in WT mice increased at 20 and 
32. The monocyte/macrophage accumulation occurs later: in WT (32 weeks), but IL-10/12-/- 
mice already had marked increases at 20 weeks (Figure 5.8B). Consistent with this finding, 
the histologic images confirm that the irradiated IL-10/12-/- mice had numerous foamy 
macrophages accumulating in their lungs as early as 20 weeks (Figure 5.8C). In summary, 
these findings from the relatively TH1-deficient and TH2-enhanced IL-10/12-/- mice support 
n 
 of 
, we analyzed TH1, TH2, and TH17 cytokine gene 
expression by quantitative RT-PCR. As expected, the IL-10/12-/- mice, which showed a TH2-
skew response in murine Schistoma fibrosis model, had very low mRNA expression of the 
H1 cytokine IFN-γ both before and after irradiation. Furthermore, the mRNA expression of 
the 1 T 
mic
 
 
 
 
our other findings that TH2 cells are crucial mediators of radiation pneumonitis and fibrosis. 
5. Cytokine gene expression in IL-10/12-/- and WT mice after thoracic irradiatio
To investigate the possible mechanisms for the pathologic differences seen in the lungs
irradiated IL-10/12-/- and WT mice
T
TH  cytokines, IL-1β and TNF-α were relatively lower in IL-10/12-/- mice than in W
e (Figure 5.9A). The TH2 cytokines, IL-4 and IL-13 were elevated after irradiation in IL-
10/12-/- mice, and these elevations occurred earlier than in WT mice (Figure 5.9B). However,
we found striking differences in TH17 cytokine profiles between IL-10/12-/- mice and WT
mice after irradiation (Figure 5.9C). Irradiated IL-10/12-/- mice displayed an earlier onset of 
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Figure 5.8 Inflammatory cell infiltrates in the lungs of irradiated WT and IL-10/12-/- mice. A. 
Greater infiltration of CD4+ T cells into the lungs of IL-10/12-/- mice than WT mice after 
thoracic irradiation. B. Macrophage/monocytes accumulation was increased in the lungs of 
irradiated IL-10/12-/- compared to WT mice. C. Arrows indicate foamy macrophages in 
H&E staining of irradiated mouse lungs. Control = non-irradiated; 20W-IR = 20 weeks post-
irradiation; 32W-IR = 32 weeks post-irradiation. Values shown are the means±SEM of 3-6 
mice per group.*p<0.05, compared to control; # p<0.05, compared to WT at same time point; 
& p<0.05, compared to WT at 32 weeks. 
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Figure 5.9 continued on next page 
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 Figure 5.9 mRNA expression of TH1, TH2 and TH17 cytokines in the lung homogenates from 
the irradiated WT and IL-10/12-deficient mice. Total RNA was isolated from the left lungs at 
0, 1, 4, 8, 12, 16, 20, and 32 weeks post-irradiation for analysis by quantitative real-time PCR. 
Data are presented as the fold change in gene expression normalized to an internal control 
gene (Gus) and relative to a calibrator sample (non-irradiated WT mouse). A. TH1 cytokines 
interferon gamma (IFN-γ), IL-1β, and TNF-α; B. TH2 cytokines IL-4 and IL-13; C. TH17 
related cytokines IL-17, IL-6, IL-21 and TGF-β1.  *p < 0.05, compared to nonirradiated 
controls of the same genotype. Data for IL-10/12-deficient mice not shown because no 
mouse of this genotype survived past 27 weeks. 
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increased IL-17 expression than in WT mice, increasing significantly at 4 weeks and 
approaching 10-fold higher levels by 20 weeks with associated very low IFN-γ levels. In 
contrast, IL-17 gene expression in irradiated WT mice increased at 8-16 weeks, returned to 
basal level at 20 weeks and again increased 10-fold by 32 weeks. Another TH17 cytokine, IL-
21, also showed an earlier onset of elevation in irradiated IL-10/12-/- mice. TGF-β1 and the 
TH2 cytokine, IL-6, both of which are required for TH17 differentiation, also had a similar 
pattern of elevations in irradiated IL-10/12-/- mice. It is notable that IL-4 expression, which 
suppresses TH17 differentiation, was lower in irradiated IL-10/12-/- mice than in WT mice at 
20 weeks.  Moreover, increased IL-17 expression was not observed in radiation fibrosis-
resistant neither CCL3-/- nor CCR1-/- mice (Figure 5.10). Together, these data support TH2 
and TH17 cells as mediators in radiation lung fibrosis. 
Lastly, we investigated whether there were differences in Treg cells, which suppress 
-/-
f 
ys, 
6. Increased IL-17 producing CD4+ T cells in irradiated IL-10/12-/- mice  
To characterize the IL-17 producing cells present in the lung of irradiated mice, IL-17 
tracellular staining was performed. We found that in contrast to CD8+ T cells, lung CD4+ T 
ells represent the critical T cell subset expressing a polarized TH17 cytokine response.  
immune responses in our model. Although Foxp3 expression in irradiated IL-10/12  mice 
was relatively higher than WT mice, Foxp3+ Treg cells in IL-10/12-/- mice may not function 
normally since IL-10 is one of cytokines Treg cells secrete in their roles as suppressors o
immune responses. Thus, we tested Treg function in IL-10/12-/- mice in suppression assa
but found that they functioned normally (Figure 5.11). 
in
c
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Figure 5.10 IL-17 expression in the lung homogenates from the irradiated WT, CCL3-
def
lungs at 0, 1, 4, 12, 20, and 32 weeks post-irradiation for analysis by quantitative real-time 
control gene (Gusb) and relative to a calibrator sample (non-irradiated WT mouse). *p < 0.05, 
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igure 5.11 Treg cells in IL-10/-deficient mice have normal suppression function by in vitro 
Treg suppression assay. Stimulators (1 × 105) were incubated with responders (WT 
 mice. 
 
 
 
 
 
 
 
 
 
Treg 1:1 1:2 1:4 1:8 1:16 No Treg
0
2.5x104
5.0x104
7.5x104
1.0x105
1.2x105
1.5x105
1.8x105
WT Tregs
IL-10/IL-12-/- Tregs
F
CD4+CD25- T cells, 1 × 105) and various ratios of Tregs from WT or IL-10/-deficient
Cultures were incubated for 3 days at 37°C and 1 µCi 3H-thymidine was added for the last 
16 hours of culture. Incorporation of 3H-thymidine was assessed. 
 
 
 127
Consistent with our gene expression data, there was 3-4 fold increase of IL-17 producing 
CD4+ T cells in IL-10/12-deficient mice at 20 weeks after irradiation (Figure 5.12). In 
contrast, the percentage of IL-17 producing CD4+ T cells in WT mice did not change at this 
time point. Taken together, these data support a role for TH17 cells in promoting radiation 
lung injury in WT and IL-10/12-/- mice, while absence of TH17 cells in irradiated CCR1-/- 
mice is associated with the radioprotected phenotype. 
We plan to do IL-17 intracellular staining on WT mice at 32 weeks post-irradiation as 
we expect WT mice also have increased IL-17 producing CD4+ T cells by that time point. 
7. Study on IL-17 receptor A-deficient mice (ongoing) 
To confirm the role of IL-17 signaling pathway in radiation-induced lung injury, IL-17 
diation (100% vs 62% at 28 weeks, p<0.05). 
receptor A-deficient mice (IL-17RA-/-) were treated in our radiation model. Preliminary data 
show that IL-17RA-/- mice have much improved survival compared to WT mice after 
ra
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igure 5.12 Accumulation of IL-17-producing CD4+ T cells in IL-10/12-deficient mice at 20 
weeks after irradiation. Lung leukocytes were isolated from irradiated mice. Isolated cells 
ere stimulated with PMA, ionomycin, and Brefeldin, and then, Intracellular cytokine IL-17 
staining was performed. Flow cytometric analyses of TH17 cells from (A) IL-10/12-deficient 
ice, (B) WT mice. The percentages of IL-17 CD4+ T cells are shown in the upper right 
quadrant of each density plot. 
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V.D. Discussion 
owever, specific roles for specific subtypes of inflammatory cells have thus far been poorly 
nderstood in the pathogenesis of radiation-induced lung injury, particularly as regards 
brosis. Evidence from several other models of lung fibrosis suggests that T cells contribute 
gnificantly to the development of pulmonary fibrosis. Our previous studies show that the 
diation fibrosis-resistant CCL3-deficient and CCR1-deficient mice have much less 
filtration of CD4+ and CD8+ T cells into the lung after thoracic irradiation, suggesting that 
ese cells may, at least part, mediate radiation pneumonitis and fibrosis. 
The present studies, using CD4-deficient and CD8-deficient mice in our model, 
owed that in the absence of CD4+ T cells, irradiated mice had improved survival, reduced 
ulmonary fibrosis and preserved lung function, whereas the absence of CD8+ T 
mphocytes exacerbated radiation-induced pulmonary fibrosis. These findings suggest that 
e recruitment of CD4+ T cells to the lung is a critical step in the immune and fibrotic 
sponse to radiation. 
ggests that TH2 cytokines, e.g., IL-4 and IL-13, promote fibrosis by stimulating fibroblast 
cretion of extracellular matrix proteins, types I and III collagen and fibronectin, while TH1 
ytokines, e.g., IFN-γ, attenuate these fibrotic processes. Our prior studies showed that, in 
ontrast to WT mice, the fibrosis-resistant CCR1-deficient mice had slightly increased 
xpression of the TH1 cytokine IFN-γ  and significantly reduced expression of TH2 cytokines 
A variety of inflammatory cells are recruited into the lungs after thoracic irradiation, 
h
u
fi
si
ra
in
th
sh
p
ly
th
re
Naive CD4+ T helper cells can differentiate into one of three lineages of effector T 
helper cells - TH1, TH2 or TH17 cells, each of which produces characteristic cytokines. 
Evidence from the bleomycin model of lung fibrosis and other models of solid organ fibrosis 
 su
se
c
c
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after thoracic radiation. Cytokine profile analyses from irradiated WT lungs also showed 
increas
osis. 
r diminished (after 20 weeks). IL-4 expression was also increased at 8-
20 wee
ed protein levels of the TH2 cytokines IL-4 and IL-13.  Moreover, IL-10/12-deficient 
mice, which display a TH2-skewed response in murine model of hepatic and lung fibrosis 
[210], had even more severe and earlier onset of radiation pneumopathy than WT mice. IL-
10/12-deficient mice died from radiation lung injury much earlier than WT: no IL-10/12-
deficient mice survived after 27 weeks, while 68% WT mice survived at this point. IL-10/12-
deficient mice developed diffuse pulmonary fibrosis much earlier after irradiation (12 weeks 
earlier than WT). The earlier onset of elevation of IL-4 and IL-13 in these mice suggests that 
these cytokines and TH2 cells contribute to the earlier development of fibr
Interestingly, we found increased IL-17 expression in the lungs of both irradiated WT 
and IL-10/12-deficient mice, but not in the radioprotected CCR1-deficient mice. Consistent 
with the earlier onset of radiation injury we saw in these mice, IL-10/12-deficient mice also 
had an earlier onset of increased IL-17 expression after irradiation than WT mice. At an early 
stage after irradiation (8-16 weeks), WT mice showed some TH1 responses by increasing IL-
1β expression that late
ks but also decreased later (32 weeks).  In contrast, IL-13 expression increased 
gradually to a maximum 4-fold increase over basal levels at 32 weeks. Thus, the TH2 
cytokine IL-13 may be more important than IL-4 in the development of radiation-induced 
lung fibrosis. IL-17 expression increased slightly at some points before 20 weeks but 
returned to normal levels until achieving a maximum 10-fold increase at 32 weeks.  In 
summary, the trends of cytokine changes we saw after thoracic irradiation in WT mice 
indicate a transition from TH1 responses to TH2 and TH17 responses occurs around 20 weeks 
(Figure 5.13). The irradiated IL-10/12-deficient mice showed a similar correlated with the  
 131
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Figure 5.13 Gene expression patterns of T 1, T 2 and T 17 cytokines in the lungs of 
irradiated WT and IL-10/12-/- mice. The fold changes of cytokine expression were generated 
by comparing with WT non-irradiated mice. (A) Fold change in mRNA expression of 
cytokines in WT mice. (B) Fold change in mRNA expression of cytokines in IL-10/12-
deficient mice.  
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pattern, but had an earlier shift toward TH2 and TH17 responses (at 12-16 weeks), that again,  
earlier onset of lung fibrosis. 
 Consistent with our cytokine gene expression data, the intracellular cytokine staining 
data also showed that the frequency of IL-17 producing CD4+ T cells in the lungs of IL-
10/12-deficient mice increased several fold at 20 weeks post-irradiation: this was not seen in 
irradiated WT mice at the same time point. To further investigate the importance of the IL-17 
signaling pathway in radiation-induced lung fibrosis, we have now irradiated the IL-17 
receptor A-deficient mice. The preliminary results show that IL-17RA-deficient mice have 
much improved survival after thoracic irradiation (100% survived to 28 weeks). We expect to 
find significant protection from radiation-induced lung inflammation and fibrosis in IL-
17RA-deficient mice. 
The mechanisms by which IL-10/12-deficient mice have an earlier shift toward TH17 
phenotype in the lung after irradiation is yet unknown. One possibility is that Treg cells in 
IL-10/12-/- mice may not function normally as in the WT mice since IL-10 is one of 
cytokines Treg cells secrete to suppress immune response. However, comparison of Treg cell 
function of WT and IL-10/12-/- mice in in vitro suppression assays suggest that Treg function 
is adequate in IL-10/12-/- mice. 
TH17 cells play a critical role in sustaining inflammatory responses. Recently they 
have been suggested to be involved in the pathogenesis of fibrosis [206, 208].  Our findings 
support the critical role of T 17 cells in radiation-induced lung fibrosis. The irradiated IL-
eposition in the lungs. IL-17 also can directly mediate the accumulation of macrophages. 
H
10/12-deficient mice, with extensive TH17 cells expansion in the lungs after thoracic 
irradiation, also had markedly increased accumulation of macrophages and collagen 
d
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For example, an anti-mouse IL-17 mAb reduced the accumulation of macrophages in 
allergen-induced airway inflammation [205, 211]. IL-17 also induces the migration of blood 
rosis.  
 hat the imbalance of TH1, TH2 or TH17 cells is important to 
the dev
monocytes from sensitized and allergen-challenged mice inflammation [205, 211]. The 
mRNA expression of MMP-9 by airway neutrophils and macrophages in vivo was down-
regulated by anti-IL-17. Il-17 also increased the survival of macrophages in a concentration-
dependent manner. This IL-17-based survival advantage may result from increased FAS 
antigen expression selectively in bronchoalvelar macrophages, as FAS-antigen functions in 
the major extrinsic pathway of apoptosis [205, 211]. Thus, the increased CD4+ TH17 cells in 
lungs after irradiation may promote the accumulation and survival of macrophages, which 
are also major source of TGF-β, and which, in turn, acts on fibroblasts to increase collagen 
synthesis and cause fib
Of interest, significant number of IL-17 producing cells were neither CD4 nor CD8 
negative, but Thy1.2 positive in irradiated mouse lungs. It is worth defining what these cells 
are, since CD4-deficient mice only showed partial protection from radiation-induced lung 
injury, suggesting that other IL-17-producing cells, like δγ T cells, may potentially involve in 
the development of radiation lung injury.  
In summary, we found t
elopment of lung inflammation and fibrosis induced by thoracic irradiation.  Our data 
are the first to indicate an important role of CD4+ TH17 cells in radiation-induced lung injury. 
CD4+ TH17 cells may promote macrophage recruitment and survival and thus exacerbate 
lung fibrosis. Studies are ongoing to confirm the necessity of the IL-17 signaling pathway in 
the development of radiation-induced lung injury and further examine the mechanisms by 
which CD4+ TH17 cells promote radiation-induced lung fibrosis. 
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VI. Summary and Future Directions 
Radiation-induced lung injury affects many patients undergoing thoracic irradiation. 
Dissection of the cellular and molecular mechanisms mediating radiation-induced lung 
inflammation and fibrosis is the key to revealing potential novel therapeutic targets. 
Our studies, for the first time, demonstrate the critical roles of chemokines and their 
receptors in the development of radiation-induced lung injury and that a specific inhibitor of 
a chemokine receptor can block the infiltration of leukocytes and thereby ameliorate the 
progressive pneumonitis and fibrosis.  
We found that radiation-induced increases in the expression of the CC chemokine, 
CCL3, mediated the recruitment of lymphocytes and macrophages, and thereby contributed 
to the development of radiation-induced lung inflammation and fibrosis. Furthermore, we 
demonstrated that the lack of a CCL3 receptor, CCR1, is protective from radiation-induced 
lung inflammation and fibrosis. Lastly, we have shown that CCR1 blockade with a specific 
antagonist, BX471, conferred the same protective effect as the genetic deletion of the 
receptor. The radioprotection we saw with CCR1 deficiency results from reduced lung 
infiltration by lymphocytes and monocytes/macrophages and an associated reduction of the 
profibrotic cytokines, TGF-β, IL-4 and IL-13. Cumulatively, these observations, for the first 
time, demonstrate that CCR1 blockade may offer a promising therapeutic strategy to reduce 
radiation-induced lung injury. However, since thoracic radiation treatment is given for 
patients with tumors, it is also crucial to understand the effects of CCR1 deficiency on tumor 
growth and metastasis before using CCR1 antagonists for preventing radiation lung injury in 
patients. Further study on the effects of BX471 on tumor growth and metastases are ongoing. 
Our research is the also first to demonstrate that the imbalance of TH1, TH2 or TH17 
cells is important for the development of radiation-induced lung inflammation and fibrosis. 
Cytokine analyses of whole lung homogenates at various time points after irradiation showed 
a predominant TH2 and TH17 phenotypes in lungs of irradiated mice. A shift toward TH2 and 
TH17 responses correlated with the development of radiation lung fibrosis. Our findings 
(chapter V) indicate the involvement of CD4+ TH17 cells in radiation fibrosis. Confirmatory 
studies of thoracic irradiation using mice with IL-17 receptor A-deficiency are ongoing. 
Together, these studies will clarify the role of the IL-17 signaling pathways in the 
pathogenesis of radiation lung injury. Further studies are also needed to determine the 
mechanisms by which IL-17 mediates radiation lung injury. Additionally, we should identify 
the role of other IL-17 producing cells, such as gammadelta T cells and NKT cells, in our 
model. 
In contrast to the radioprotected CCL3-deficient and CCR1-deficient mice, we found 
marked accumulation of macrophages in the lungs of the radiation injury-sensitive WT and 
IL-10/12-deficient mice, suggesting that macrophages are also important in the development 
of radiation lung inflammation and fibrosis. A new transgenic mouse (CD11b-DTR) in which 
macrophages could be selectively depleted offers a powerful new tool to study macrophages 
[72].  This transgenic mouse has a diphtheria toxin (DT) inducible system that transiently 
depletes macrophages. The transgene insert contains a fusion product involving simian 
diphtheria toxin receptor and green fluorescent protein under the control of the human 
ITGAM (integrin alpha M) promoter (CD11b). Therefore, macrophages could be specifically 
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ablated by a simple intravenous injection of DT at specific time intervals after irradiation to 
determine their role in radiation lung injury.  
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